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Preface 
This report on Stakeholder Perspectives on Perception, Assessment, and Management of the Potential 
Risks of Nanotechnology is the result of the National Nanotechnology Initiative (NNI) workshop held on 
September 10–11, 2013, in Washington, DC. The goal of the workshop was to assess the state of 
research progress in risk assessment, management, and communication as it aligns with the Risk 
Assessment and Risk Management Methods research area of the 2011 NNI Environmental, Health, and 
Safety (EHS) Research Strategy. The workshop was initiated and organized by the Nanotechnology 
Environmental and Health Implications (NEHI) Working Group of the Nanoscale Science, Engineering, 
and Technology (NSET) Subcommittee under the Committee on Technology of the National Science and 
Technology Council, with the assistance of the National Nanotechnology Coordination Office. The 
workshop facilitated a vigorous stakeholder discussion of the key elements needed to assess, manage, 
and communicate potential risks associated with the use of nanomaterials and nanotechnology-enabled 
products, with a focus on practical tools that might be used by non-Federal decision makers in their 
consideration of potential risks. The workshop was planned by a multi-sector team, including members 
from academia, industry, not-for-profit entities, and the Federal Government, to ensure active 
participation from a broad range of stakeholders. As a result, this report provides examples of risk 
management, assessment, and communication approaches as described by a diverse set of workshop 
participants, which will assist Federal agencies in the implementation of the risk assessment and 
management research needs outlined in the 2011 NNI EHS Research Strategy. 
On behalf of the NSET Subcommittee, we thank Treye Thomas, Jeffery Steevens, and Igor Linkov for 
taking the lead in organizing and co-chairing the workshop. Thanks are also due to the NEHI Working 
Group for leading the planning effort on behalf of the NSET Subcommittee, and to the other members of 
the workshop planning team (listed on the previous page). We also thank all the speakers and 
participants for their contributions to the workshop. We trust that you will find this report to be a 
valuable resource for the NNI, the nanotechnology EHS research community, and all of the other 
stakeholders as we work together to promote the responsible development of nanotechnology for the 
benefit of the United States. 
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Executive Summary 
The goal of the National Nanotechnology Initiative (NNI) Workshop on Stakeholder Perspectives on 
Perception, Assessment, and Management of the Potential Risks of Nanotechnology (the “R3 
Workshop”) was to assess the status of nanotechnology environmental, health, and safety (EHS) risk 
science three years after the development of the 2011 NNI EHS Research Strategy and to identify the 
tools and best practices used by risk assessors to address the implications of nanotechnology. The 
workshop was successful in providing a venue for a wide range of stakeholders including Federal and 
State regulators, small and large businesses, insurance companies, academic researchers, occupational 
safety specialists, and public and environmental advocacy groups to share their perspectives on the risk 
management process and to discuss strategies and approaches for improving risk science methods. 
Another important outcome was the discussion of ways that NNI agencies can assist stakeholders in the 
responsible development of nanotechnology. 
Stakeholders participating in the workshop presented their perspectives and methods used to assess 
and manage the potential risks of nanotechnology. Difficulties in applying commonly used risk 
assessment approaches where risk is quantified as the probability of specific impact (e.g., cancer) were 
noted due to the lack of validated risk benchmarks that can be used as references. Screening-level risk 
assessment methods (e.g., control banding) incorporate risk severity scores on individual risk metrics to 
quantify overall risk, while comparative risk assessment processes and multicriteria decision analysis 
(MCDA) tools can be useful in prioritization of alternative materials or technologies. For example, 
control banding or MCDA tools can be used to screen and communicate hazard information on 
nanomaterials in the face of missing data. The use of relevant risk assessment tools, e.g., industry 
standards, guidance documents, and reference nanomaterials, was also discussed. Life cycle assessment 
(LCA) for risk-based nanotechnology development decision making was mentioned as a practice 
common across stakeholder groups. A complete list of the tools, standards, and informational 
repositories that were discussed can be found in Appendix D (p. 72). 
Research presented at the workshop shows that technical risk data alone will not enable decisions; risk 
evaluations by different stakeholders with varying biases, values, and stances can affect the perceptions 
and behaviors (e.g., investment or personal safety decisions) of consumers, regulators, developers, 
manufacturers, and insurers. 
As highlighted by the keynote speakers, stakeholder perceptions and risk communication are complex 
issues that require expert analysis to understand potentially subtle or obscure ethical complexities. 
Empirical evidence indicates that using an intuitive understanding of “risk” to respond to societal needs 
results in erroneous conclusions for nanotechnology implications, thus outlining the need for more 
robust approaches for communicating risk information to the lay public. When these considerations are 
integrated early on in the risk management process using effective risk communication, they can help 
align actual risk and perceived risk. Overall, better outcomes, such as improved understanding of 
potential risks by stakeholders, will result if these issues are explicitly addressed. 
The dialogue at the workshop between participants was robust, and although various perspectives were 
presented, some stakeholder participants emphasized the importance of developing more information 
on the potential hazards and exposure potentials of nanotechnology and how this information can 
improve existing risk analysis approaches. In cases where data are available, decision makers may not be 
clear what weight or value is appropriate to place on certain criteria or metrics in the decision 
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framework when setting safety standards and regulatory policy. For the business community, data gaps 
and public perception of risk are both highly important in terms of sustainable development, regulatory 
compliance, and market acceptance. 
Participants from the various stakeholder communities identified needs in four areas (the list below is 
not prioritized): 
• Communication Resources 
o Communication and decision tools for improved stakeholder communications and collective 
risk-based decision making. 
o Improved transparency in reporting the presence of engineered nanomaterials (ENMs) in 
applications across the supply chain. 
o Continued collaboration and communication among diverse stakeholder groups. 
• Decision Tools 
o Improved detection and characterization tools and methods for assessing exposure and the 
potential risks of ENMs. 
o Tools to address nanotechnology-related environmental, health, and safety (“nanoEHS”) 
issues at an earlier stage of product development. 
o Better integration of life cycle assessment tools and decision analysis tools with risk 
assessment to support regulatory decision making. 
• Data Resources 
o Repositories or databases to facilitate access to or organization of existing information on 
nanoEHS. 
o Methods for accessing and investigating information that could be restricted as a result of 
issues such as confidential business information (CBI) or intellectual property (IP) protection. 
o Continued toxicology studies on the effects of ENMs. 
• Standards and Guidance Resources 
o Standards and guidances to facilitate navigation of nanotechnology-enabled applications 
through the regulatory process. 
o Improved data quality and methods for reporting data used in nanomaterial risk 
assessment. 
This report paraphrases statements made by the presenters and participants. Statements should be 
taken as expressions of the views of the speakers and not the positions of the NSET Subcommittee, 
NNCO, or the NNI agencies. Chapter 9 of this report provides additional details on common themes 
discussed during the workshop. In particular, Table 9.1 (p. 52) includes a list of topics discussed by 
breakout session and stakeholder/decision-maker groups. 
 Stakeholder Perspectives on Perception, Assessment, and Management of the Potential Risks of Nanotechnology 
1 
1. Introduction 
Nanotechnology holds the potential to impact many fields of science and technology, with exciting 
applications in medicine, sensing, and battery technology, among many others. However, as products 
enter the global market, there are still questions about the potential risks and benefits of 
nanotechnology to consumers, workers, and, more generally, human health and the environment. 
The National Nanotechnology Initiative (NNI) recognizes the critical importance of environmental, 
health, and safety (EHS) research in support of the responsible development of nanotechnology. The 
2011 NNI EHS Research Strategy [1] supports the use of science-based risk analysis and risk management 
to protect public health and the environment while fostering technological advancements that benefit 
society. Engagement of all stakeholder groups in developing and communicating up-to-date EHS 
research, best practices, and applicable regulations in the area of nanotechnology risk science is 
essential to continuing the responsible development of nanotechnology. Such stakeholder communities 
include innovators, scientists, nongovernmental organizations (NGOs), industry, regulators, and the 
general public. To foster this engagement, the NNI organized a Workshop on Stakeholder Perspectives 
on Perception, Assessment, and Management of the Potential Risks of Nanotechnology (the “R3 
Workshop”) to gather information on the current state of practice in nanotechnology risk science and 
the values and perceptions of risk among the various NNI stakeholder groups. Additionally, NNI agencies 
sought stakeholder input on steps to improve the linkage of risk assessment to risk management and 
risk communication. 
About the Workshop 
The NNI R3 Workshop was held on September 10 and 11, 2013, in Washington, DC, and was sponsored 
by the Nanoscale Science, Engineering, and Technology (NSET) Subcommittee of the National Science 
and Technology Council (NSTC) Committee on Technology (CoT). The meeting was organized by a 
multisector planning team composed of representatives from academia, industry, NGOs, and members 
of the interagency Nanotechnology Environmental and Health Implications (NEHI) Working Group of the 
NSET Subcommittee. The Consumer Product Safety Commission (CPSC) and the Department of Defense 
(DOD) co-chaired the planning team, bringing together more than 130 participants from national and 
WHAT IS NANOTECHNOLOGY? 
Nanotechnology is the understanding and control of matter at dimensions between 
approximately 1 and 100 nanometers, where unique phenomena enable novel applications. 
Encompassing nanoscale science, engineering, and technology, nanotechnology involves 
imaging, measuring, modeling, and manipulating matter at this length scale. 
A nanometer is one-billionth of a meter. A sheet of paper is about 100,000 nanometers thick; 
a single gold atom is about a third of a nanometer in diameter. Dimensions between 
approximately 1 and 100 nanometers are known as the nanoscale. Unusual physical, 
chemical, and biological properties can emerge in materials at the nanoscale. These 
properties may differ in important ways from the properties of bulk materials and single 
atoms or molecules. 
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State governments, organized labor, the insurance industry, small businesses, and academia. An 
additional 106 viewers participated via a live webcast [2]. 
This workshop builds upon a previous series of meetings on nanotechnology environmental, health, and 
safety (nanoEHS) research and risk assessment held by the NNI, which culminated in a March 2010 
“capstone” workshop [3]. The goal of this series of meetings was to gather input from the research and 
other stakeholder communities on nanoEHS research needs—input that was taken into account in the 
development of the 2011 NNI EHS Research Strategy. The R3 Workshop aimed to assess the status of 
nanoEHS risk practice three years after the development of the 2011 NNI EHS Research Strategy. The 
workshop was deliberately participatory, with collaborative discussions, presentations, and breakout 
sessions involving multiple stakeholder groups. 
This workshop was designed to gather data in a “top-down” fashion that focuses on decision makers, 
rather than a “bottom-up” approach that begins with data collection ([4], see Figure 1.1;). This method 
puts the focus on identifying types of decisions and decision-maker needs in order to guide 
nanotechnology risk assessment and risk management going forward. 
With these considerations in mind, the agenda included the following sessions: 
• Introductory Session: NNI Needs. 
• Plenary: Stakeholder Perspectives. 
• Keynotes: Stakeholder Risk Perception. 
• Breakouts: Types of Decisions and Types of Decision Makers. 
• Roundtable Discussions and Summaries. 
Workshop planners and the NNI agencies aimed for the R3 Workshop to achieve the following: 
• Facilitation of stakeholder inputs on the state of progress of tools and methods used in risk 
analysis. 
• Identification of stakeholder values that inform risk-based decision making, and potential 
integration of these values and perceptions into a practical framework for risk communication. 
• Determination of steps to improve the linkages of risk assessment to risk management and risk 
communication. 
• Highlighting of ongoing and future challenges impacting the assessment, management, and 
communication of the potential risks of nanotechnology. 
The above outcomes are needed to help advance the NNI’s nanoEHS risk assessment and risk 
management strategy. 
About the Report 
This report is a summary of the key topics discussed at the NNI R3 Workshop and paraphrases 
statements made by the presenters and participants. Statements should be taken as expressions of the 
views of the speakers and not the positions of the NSET Subcommittee, the National Nanotechnology 
Coordination Office (NNCO), or the NNI agencies. Chapter 1 summarizes the workshop objectives, 
methodology, and anticipated outcomes. Chapters 2 and 3 summarize the keynote presentations: 
Chapter 2 discusses the process of risk analysis and the characteristics of effective risk analysis and risk 
communication methods; Chapter 3 reviews NNI-funded empirical data on nanotechnology risk 
perception among NNI stakeholder groups and several related implications. Chapter 4 summarizes the 
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perspectives of multiple stakeholder communities on the perception, assessment, and management of 
the potential risks of nanotechnology. Chapter 5 outlines the methodology of the stakeholder breakout 
sessions involving discussion of a hypothetical “Nanoparticle X” (see sidebar on p. 25) and the charge to 
the participants in those breakouts. The discussions from the breakouts are summarized by risk decision 
type in Chapter 6 and by stakeholder community in Chapter 7. Chapter 8 discusses the outcomes of the 
roundtable discussions. In Chapter 9, recurring themes across all sessions are summarized. Appendices 
include (A) the workshop agenda, (B) a list of workshop participants, (C) a list of acronyms and 
abbreviations used in the report, and (D) a list of available tools and information repositories mentioned 
at the workshop. Additional materials related to the workshop are available 
at www.nano.gov/R3workshop [5]. 
Figure 1.1. Comparison of approaches to risk management. Top-down: Identifying types of decisions and 
decision-maker needs to guide risk assessment and risk management. Bottom-up: Moving from hazard 
identification, exposure assessment, and risk characterization toward informed decisions. (Republished with 
permission of Springer, from Risk-based standards: integrating top–down and bottom–up approaches, Linkov, 
et al., Environment Systems and Decisions 2014; permission conveyed through Copyright Clearance Center, Inc. 
[4].) 
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2. Keynote—Risk Analysis 
Summary of Remarks by Baruch Fischhoff, PhD Howard Heinz University Professor Social and Decision Sciences and Engineering and Public Policy Carnegie Mellon University 
The field of risk management has been developing for about half a century. Most large English-speaking 
countries have produced some type of document with similar steps for effective risk management, in 
which (1) the size of the risk is characterized, (2) the value of the risk is assessed, and (3) the risk is 
somehow controlled. One preferred model is from the Standards Council of Canada ([6, 7], see 
Figure 2.1), which strives for overall management of risk by focusing on communication at each step. 
Specifically, the model (1) calls for the evaluation of benchmarks after each stage of the process (a 
“reality check”) and (2) includes an explicit expectation of risk communication with stakeholders so that 
the public is not “blindsided” by a decision. This approach ensures that both actual risks and the 
concerns of the public are addressed. It can also allow technologists to solve potential problems early in 
the product design process, before financial, staff, and structural investments are made. 
The Fischhoff research group’s work on risk associated with the microscopic parasite Cryptosporidium in 
water supplies [8] illustrates how an explicit risk management model can assist the risk assessment 
process. The analysis can begin with either a bottom-up or a top-down approach; bottom-up by 
identifying the event and its potential outcomes 
(an analysis based on an event tree) or top-down 
by starting with an outcome and identifying the 
scenarios that might cause the outcome (an 
analysis based on a fault tree). Both methods can 
be used in concert to define the major risk-based 
determinant(s). Ultimately, this two-way process 
ensures that analysts integrate a variety of 
factors that are essential to risk analysis (e.g., 
characteristics of a local public health system, 
relevant regulations, and self-protective 
mechanisms—effective or not—that consumers 
could implement). An adequate risk model should 
be explicit and should accomplish the following: 
• Create clear, shared definitions of 
variables and relationships. 
• Identify critical expertise. 
• Organize existing evidence. 
• Organize emerging evidence. 
• Estimate risk and uncertainty. 
Assuming that quantitative data exist for every 
factor relevant to the risk analysis process, the 
model can be used to obtain absolute risk levels. 
Figure 2.1. Fischhoff’s preferred model of the risk 
management process, with a focus on communication. 
The flow chart shows six steps: initiation, preliminary 
analysis, risk estimation, risk evaluation, risk control, and 
action/monitoring. During the entire process, all of these 
steps interact with risk communication. (Reproduced 
from Figure 18 in [6], based on [7], courtesy of the 
Canadian Standards Association group.) 
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However, even in the absence of quantitative data, this model can still allow analysts to assess relative 
risk by (1) providing a general assessment of effectiveness for selected precautions or safeguards, and 
(2) helping to identify as well as gather relevant decision makers who can influence the risk level in the 
situation of interest. An adequate communications strategy must accompany an adequate risk model. 
This strategy includes providing the information that people need in accessible places and in a 
comprehensible form and using their feedback to inform risk managers early enough in the process to 
affect the design of the risk management framework. 
Common Pitfalls 
Assuming that risk can be defined objectively: The term “risk” can mean different things to different 
stakeholders, such that no single definition is objectively correct. The National Research Council (NRC) 
Committee on Risk Characterization recognized the critical importance of defining risk in its influential 
report, Understanding Risk [9]. This report overturned the conventional risk management model by 
suggesting that defining risk (i.e., engaging in explicit risk characterization) in the context at hand is the 
first step that risk managers must undertake. The NRC report also indicated that because risk is 
informed by public values, communication with the public and stakeholder engagement must occur in 
order to define risk correctly. 
For instance, whereas certain risk analysts may implicitly assume that risk is defined as the probability of 
premature death (i.e., the probability that someone in a given population will die as a result of the new 
technology), others may assume that risk is defined as the expected life years lost (i.e., the number of 
years of life lost as a result of the new technology, which will be higher when younger people die). In the 
late 1970s and early 1980s, researchers addressing risk in the context of the nuclear power industry 
modeled risk differently if deaths occurred catastrophically (i.e., all at once), as opposed to chronically 
(i.e., over an extended period of time). Thus, a catastrophic but very low-probability event may be 
weighed differently than an event causing the same number of deaths distributed across several years, 
depending on societal needs or values. Risk analysts also should consider how outcomes are distributed 
over time: should risk that will only be realized at a future date be given the same weight as immediate 
risk [10]? There are many possible risk outcomes, including injuries, illnesses, preterm births, child abuse 
and neglect, and unrealized potential; deciding which definition to accept is a non-trivial, ethics-based 
choice. 
When defining risk, consideration should be given as to whether the risk is either [11]: 
• Distributed equitably. 
• Assumed voluntarily. 
• Catastrophic. 
• Well understood. 
• Controllable. 
• Dreaded. 
• Borne by future generations. 
Any decision regarding the definition of risk will be controversial and will likely not be ethically or 
socially acceptable unless stakeholders are involved in defining that choice. Even in the presence of an 
open dialogue, the terms of any analysis will embody values that favor certain interests. As a result, 
common metrics across contexts will obscure ethical issues unless adopted by a credible public process 
because every context has its own complexity. For example the many different ways that one might 
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want to “discount” future outcomes in a risk analysis [10] demand communication and stakeholder 
involvement so that this consideration can be explicitly addressed when defining risk. 
Limiting analyses to readily available experts and evidence: Most organizations initially approach risk 
with their preexisting set of experts. Because risk analysis depends on a vast array of factors, it is 
unlikely that any one organization will have a full set of experts capable of providing all of the relevant 
proficiency. The Fischhoff research group’s work on the public health risk posed by Cryptosporidium 
intrusion into domestic water supplies illustrates this point [8]. This risk analysis model depended on 
factors including utility treatment options, health department awareness, and media coverage. Although 
the research team had reviewed the literature and had created putative estimates of risk, experts 
familiar with each system were also consulted. Without these other experts, this model would have 
been incomplete and potentially misleading; the researchers would not have discovered a fundamental 
flaw in their system for developing public warnings regarding Cryptosporidium contamination. 
In terms of only using readily available data, summary measures of uncertainty are difficult to find, even 
though they are badly needed by decision makers. For various reasons, an organization’s leaders might 
not feel that representing uncertainty is justified. However, the behavioral literature shows that much of 
the difficulty in understanding uncertainty comes not from numbers or concepts, but from the 
murkiness of the events being described [12]. An organization that does not support the representation 
of uncertain knowledge may develop a communication problem. Therefore, researchers should make an 
effort to effectively communicate uncertainty to decision makers and the public [13]. 
Choosing to “fly blind” when communicating with stakeholders: To communicate responsibly with 
stakeholders, risk managers must do stakeholder research. There are two main reasons for this: 
(1) personal intuitions regarding communication, even with people we know well, are often faulty and 
(2) human behavior is always complex. Much of psychology is dedicated to documenting ways in which 
we misunderstand one another. Misunderstandings can be exacerbated when the audience does not 
trust the communicator, does not know the communicator, has a different background than the 
communicator, or has other goals in mind. One major reason for miscommunication is the “common 
knowledge effect.” This occurs when the communicator overestimates the extent to which the audience 
shares his or her knowledge and may result in the communicator failing to provide critical information. It 
is difficult to predict how communicating information will affect human behavior. Based on the 
literature, several principles guide people’s judgments and choices: 
• Principles of judgment 
o People are good at tracking what they see but not at detecting sample bias. 
o People have difficulty projecting nonlinear trends. 
o People have a limited ability to evaluate the extent of their own knowledge. 
o People have difficulty imagining themselves in other visceral states. 
o People can be affected by transient emotions. 
• Principles of choice 
o People can be prisoners to sunk costs, hating to recognize losses. 
o People dislike uncertainty. 
o People consider the return on their investment in making decisions. 
o People are insensitive to opportunity costs. 
o People may not know what they want, especially when asked novel questions. 
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A priori, even if you know the literature, you cannot predict which principle will be important and how it 
will interact with a particular audience and a particular message. There is no responsible way of 
communicating without collecting evidence. Just as a risk manager has a fiduciary responsibility to 
prevent rejection of his or her client’s product by an uncomfortable public, anybody who puts others at 
risk or is trying to provide benefits that might be lost if the process fails has an ethical responsibility. Risk 
managers who choose not to test their message are choosing to “fly blind,” putting their own enterprise 
and their stakeholders in peril. 
Proposals for Avoiding the Pitfalls 
Overall, a risk management framework requires domain and subject matter experts, risk and decision 
analysts who can identify the relevant facts, behavioral scientists who can create an effective 
communications strategy, and systems specialists and practitioners who can ensure that the entire 
enterprise is functional. 
Create an independent resource center: An independent, permanently funded resource center with 
scientific support would assist the risk management process. An effective risk management endeavor 
requires a fairly complicated skill set that is best satisfied by experts in each area. These groups are not 
often in communication with each other and do not know how to initiate a joint risk management 
endeavor. A competent resource center should have sufficient resources and participants to handle 
outreach to stakeholder communities and to serve as a point of contact for “inreach” among experts 
capable of providing publication-quality scientific support. The envisioned resource center should have 
the following functions: 
• Provide quality assurance from researchers willing to commit a portion of their time for the 
public benefit (hopefully with institutional support). 
• Facilitate economies of scope. 
• Pool lessons learned. 
• Anticipate problems. 
• Involve academic researchers who are not willing or able to commit time or resources to applied 
research. 
Standardize procedures for making and communicating decisions: When multiple groups involved in a 
single endeavor communicate in different ways, the audience will have to orient itself to each style. This 
makes the decision-making procedure challenging. If a standard procedure for making and 
communicating decisions were implemented, the efficiency of the process could be significantly 
improved. One example of an effort to standardize communication is the process promulgated by the 
Food and Drug Administration (FDA) for both conducting and communicating its licensing decisions 
under the Prescription Drug User Fee Act [14]. This process is an interesting compromise between 
making it comprehensible to people and making something experts are comfortable saying. In the FDA 
process, all evidence must be accompanied by an assessment of uncertainty. The FDA method also 
clearly distinguishes between the evidence and the reasons and conclusions that lead to each decision. 
Another group systematically summarizes drug testing evidence specifically for patients [15]. Complex 
information can be understood by most of the public if the communicator uses effective communication 
methods informed by research. 
Develop a shared understanding by developing a common knowledge of essential scientific 
approaches: Risk managers should seek fluency, rather than technical mastery, in a range of risk 
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management and analytical methods. Few analytical approaches have made their way through peer 
review; therefore, it is advantageous and not prohibitively difficult for risk managers to know a little bit 
about different analytical methods so that they can recognize classes of problems that they might not 
otherwise detect [16, 17]. Every competent risk manager should know something about the following 
essential analytical methods: 
• Risk analysis. 
• Decision analysis. 
• Signal detection theory. 
• Game theory. 
• Economics. 
• Behavioral psychology. 
• Communications. 
In conclusion, the development of a common knowledge of essential scientific approaches can allow for 
efficient risk management by enabling the sharing of information among stakeholders. Such an 
understanding will enable effective communication and create more informed stakeholder 
communities. Finally, several resources that are points of access for understanding risk management 
methods are provided in Table 2.1. 
Table 2.1. Resources on risk management 
Title of Resource Author(s) 
The Science of Science Communication PNAS [18]  Fischhoff, B., & Scheufele, D. (Eds.), 2013 
Communicating Risk and Benefits: An Evidence-Based 
User’s Guide (FDA) [19]  
Fischhoff, B., Brewer, N., & Downs, J. (Eds.), 2011 
Risk: A Very Short Introduction [7]  Fischhoff, B., & Kadvany, J., 2011 
Thinking, Fast and Slow [20]  Kahneman, D., 2009 
Uncertainty [21]  Morgan, M. G., Henrion, M., & Small, M., 1990 
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3. Keynote—Nanotechnology 
Multi-Stakeholder Risk 
Perception: Implications for Risk 
Analysis, Management, and 
Communication 
Summary of Remarks by Barbara Herr Harthorn, PhD Professor of Anthropology Director, Center for Nanotechnology in Society University of California, Santa Barbara 
Responsible and ethical risk analysis and communication is a key part of responsible development of 
nanotechnology. These require having good, empirical evidence about both the technical risks and about 
society’s perceptions of risk. Both actual and perceived risk are important not only for normative, ethical 
reasons but also for instrumental reasons, to achieve better outcomes. This overview of the diverse 
stakeholder perceptions of nanotechnology risks and their potential implications for risk management 
and decision making is based mainly on the research of the Center for Nanotechnology in Society at the 
University of California, Santa Barbara (CNS-UCSB), funded by the National Science Foundation. 
The need for a common language is evident throughout the discussions of this workshop. The definition 
of “responsible development” endorsed by the National Research Council (NRC) of the National 
Academy of Sciences provides an ethical framework for the NNI risk management endeavor. According 
to a 2006 NRC report, responsible development of nanotechnology “implies a commitment to develop 
and use technology to help meet the most pressing human and societal needs, while making every 
reasonable effort to anticipate and mitigate adverse implications or unintended consequences” 
[22]. Based on this definition, responsible development is entwined within a risk–benefit framework 
where the benefits aim to answer the needs of society. The empirical evidence indicates that one cannot 
rely on intuitive understanding of “risk” or “benefit” to respond to societal needs. Various stakeholders 
with diverse backgrounds will likely have differing perceptions with respect to what constitutes both 
benefits and risks in nanotechnology development. CNS–UCSB has investigated the risk/benefit 
perceptions of six stakeholder groups: 
• Scientists and engineers synthesizing novel materials and incorporating them into increasingly 
complex molecular devices and systems. 
• NanoEHS researchers (toxicologists) working to characterize the hazards of numerous 
manufactured nanomaterials and nanotechnology-enabled products in a large range of 
environmental contexts. 
• Regulators attempting to determine a safe course forward that will ensure public safety without 
impeding economic development. 
• Industry leaders and workers concerned with safety and quality control while maintaining an 
economically viable future. 
• NGOs, or the “activated public,” focused primarily on environmental and consumer product 
safety risks or about democratic participation itself. 
• Lay publics, who generally are not included in these discussions but often are implicated as 
participants, as imagined downstream consumers. 
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In order to obtain an accurate, representative sample of public perceptions of emerging technologies, 
research must be comprehensive and deliberative. Relevant publics include representative sample 
groups, “invited publics” (quasi-representative), and “self-selected” publics. The self-selected public 
comprises individuals who are self-motivated to attend advertised events, including NGOs, whereas the 
invited public may not even know that the research topic qualifies as, for example, an emerging 
technology. It is important to note that at least one study in the UK has indicated that self-selected 
public groups tend to have a perception of risk that is higher than that of the general public [23]. 
Studies on Stakeholder Risk Perception 
Summarized here are several CNS-UCSB studies on public perceptions of risk and the complex cognitive 
and affective drivers of risk perception, conducted through both survey-based, experimental 
quantitative research and qualitative/deliberative evaluations (i.e., mixed methods research). 
Risk perception among members of the public: A meta-analysis of 22 surveys on public perception of 
nanotechnology was conducted between 2002 and 2009 [24]. These surveys were conducted in North 
America, Europe, and Japan. The results showed that public perception of nanotechnology was 
benefit-centric: Among those who did not indicate uncertainty, members of the public who believed 
that the benefits outweighed the risks outnumbered those who believed that the risks outweighed 
the benefits by a ratio of approximately three to one ([24], see Figure 3.1). However, because on 
average 44% of people indicated uncertainty, this analysis also highlights the potential for a future 
change in public perception and probably indicates that large portions of the public are unfamiliar 
with nanotechnology (over 50% in some surveys). The large “not sure” results of this study are 
unusual in the risk analysis arena when conducting this type of study. 
A comparative review of 18 different deliberative 
research projects also found benefit centricity to 
be widespread with respect to nanotechnology risk 
perception [25]. However, the same study also 
discovered a phenomenon of “latent 
ambivalence,” which manifests around three 
views: (1) skepticism toward the government and 
industry, (2) a concern about who represents the 
public’s interests, and (3) questions regarding 
whether a product is needed at all. These concerns 
represent social, not technical, risk issues, and they 
are the predominant concerns voiced in 
deliberative forums, even when technical risk 
information is presented during the deliberations. 
Thus, increased knowledge and awareness do not 
affect this latent ambivalence. 
Another research example indicated that the trust 
asymmetry principle (i.e., that trust is much easier 
to lose than it is to gain) will prevail in the 
nanotechnology context. In one of their studies, 
CNS-UCSB researchers conducted a phone survey 
to assess how plausible positive and negative 
Figure 3.1. Pie chart showing public perceptions of 
nanotechnology risks and benefits. The results are 
based on a quantitative meta-analysis of 22 studies 
from 2002–2009 in North America, Europe, and Japan. 
The responses were benefit-centric, with nearly half of 
respondents stating that the benefits are equal to or 
greater than the risks. However, the most frequent 
response was that of uncertainty, showing a high 
potential for opinions to shift. (Figure courtesy of B. 
Herr Harthorn.) 
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scenarios relating to nanoEHS effects, nanotechnology-related industry actions, and nanotechnology 
regulation would affect public perceptions of nanotechnology [26]. The negative scenarios decreased 
public trust more than the positive scenarios increased public trust, and trust was lost more easily when 
bad news followed good news. For example, if the benefits of new technology were advertised and 
emphasized to the public and news about risk or adverse effects followed, public trust would suffer a 
greater amount of damage than if balanced news were given throughout the process. 
The results of an in-progress web survey by CNS-UCSB researchers reveal interesting aspects of the 
public’s opinion about what constitutes an acceptable amount of environmental risk [27]. The results 
show that the public has a fairly nuanced idea of what constitutes “responsible development” of new 
technology. Specifically, the public is interested in the degree to which informed consent is given to 
develop new technology, the degree to which issues of equity and power are resolved ethically, the 
value given to the public’s role, and the amount of trust that is held by the acting institutions. 
Race and gender can also be important in public deliberation about risk [28], resulting in subtle and overt 
group dynamics. For example, men speak more than women and use more intrusive interruptions 
during deliberations about nanotechnology; whites use more intrusive interruptions than people of 
color; women use more backchannels, cooperative overlaps, and self-disclosure when discussing health 
and human enhancement applications as opposed to energy and environmental applications; and men’s 
patterns of talk do not vary when the application discussed varies. These dynamics are found in many 
other decision-making situations regarding social issues; their significance is that both subtle and overt 
group dynamics play major roles in deliberative settings, are very difficult to disentangle, and are not 
well studied. The important aspect is that these studies show the dynamic that one can expect when 
dealing with decision makers who have varying social positions. Ultimately, the public dialogue on 
nanotechnology, particularly early in development, is likely to veer from technical risk to societal 
implications. 
Risk perception among NGOs: The CNS-UCSB research group is approaching the topic of 
nanotechnology risk perception among NGOs by analyzing English-language publications from 183 
NGOs, 88 of which are specifically “nano engaged” [29]. Of this sample, the researchers have 
preliminarily chosen 20 predominant groups and have summarized how those NGOs focus on consumer 
and environmental safety. Common goals among these groups include the following: 
• Increasing the amount of nanoEHS research. 
• Promoting labeling of commercial products containing nanomaterials. 
• Increasing government oversight of nanotechnology. 
• Engaging the public in dialogues on nanotechnology. 
The CNS-UCSB researchers found that NGO groups have paid little attention thus far to worker safety 
issues. Also, they found that in general, NGOs do not restrict their activities to specific nanomaterials, 
with the exception of nanosilver and titanium dioxide. Finally, these groups often advocate government 
action as the main focus of their social action. 
Risk perception within industry: Not much work has been done with industry. CNS-UCSB has completed 
two international surveys, in 2006 [30] and in 2010 [31]. In the more recent study, the researchers 
interviewed industry leaders from companies that handled or produced engineered nanomaterials 
(ENMs) about issues relating to risk perception for six classes of nanomaterials: carbon nanotubes (CNTs), 
heavy metals, dry powders, quantum dots, metal oxides, and other carbonaceous nanomaterials. 
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Results showed that 75% of respondents were either uncertain about the risks or that they believed that 
the risks of nanomaterials were “moderate to high.” This trend was fairly uniform across the six 
surveyed materials, indicating that risk perception among these industry leaders was not dependent on 
the materials that their companies were handling. 
The researchers then asked a series of questions regarding regulations ([31], Figure 3.2). The answers 
provide evidence that the industry prefers autonomy from governmental regulation. Typically, 
individuals with high perceived risk favor self-protection through regulation. At the same time, there 
was strong concern regarding the public response ([29], Figure 3.3). In particular, the majority of 
respondents were concerned about unwarranted public backlash and believed that the direct 
involvement of citizens in technology policy is not beneficial. 
Risk perception among experts: Three stakeholder groups may be termed “experts,” including 
(1) nanotechnology scientists and engineers, (2) regulators involved in nanotechnology-related 
regulation and nanotechnology risk assessors in the government, and (3) nanoEHS researchers. A study 
by CNS-UCSB researchers surveyed over 400 experts about their risk perceptions relating to 
nanotechnology [32]. The results of this study indicated that expert views on nanotechnology-related 
risk are significantly different from the views held by the general public, particularly in terms of 
uncertainty regarding the risks and benefits. In total, 23% of nanotechnology-related regulators, 16% of 
nanoEHS researchers, and 11% of nanotechnology scientists and engineers indicated that they “didn’t 
know” or “weren’t sure” whether the risks of nanotechnology would outweigh the benefits ([33], Figure 
Figure 3.2. Industry perceptions of risk and regulation show a preference for autonomy over regulatory 
oversight. The study asked nanotechnology companies to rank their agreement with each of statements 1–5 on 
a scale of strongly disagree, disagree, don’t know, agree, and strongly agree. The statements implied a desire 
for independence from regulation, and the majority of respondents (over 50%) agreed or strongly agreed with 
each statement. (Figure courtesy of B. Herr Harthorn.) 
1. It is reasonable to assume that industries working 
with nanomaterials will adapt or alter their safe-
handling practices when new hazards are discovered.
2. Businesses are better informed about their own 
workplace safety needs than are government agencies.
3. Industries working with nanomaterials can be trusted 
to regulate the safe handling of these materials.
4. Voluntary reporting approaches for risk 
management are effective for protecting human 
health and the environment.
5. Employees are ultimately responsible for their 
own safety at work.
Strongly agree Agree Disagree Strongly disagreeDon’t know
0% 20% 40% 60% 80% 100%
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3.4). In contrast, the surveyed members of the public who provided the same ambivalent responses 
constituted nearly the majority of respondents in a 2009 meta-analysis of 22 surveys (Figure 3.1). 
Overall, the majority of respondents from each expert community believed that the benefits of 
nanotechnology will outweigh the risks. Nanotechnology scientists and engineers—the group actually 
“in the labs”—generally showed less concern about the potential risks posed by nanotechnology than 
the other two groups did, and regulators and risk assessors in the government showed the most 
concern. The results of this study show that among experts, regulators have the least amount of 
confidence in the ability of the regulatory system to handle the challenges posed by nanotechnology. 
Additionally, the study revealed gender differences with respect to experts’ nanotechnology risk 
perceptions. The survey indicated that female experts generally perceived risk to a greater extent than 
male experts did, a finding that replicates the results of the vast majority of risk perception surveys 
considering gender. The point of this result is not just about gender, but rather that a person’s social 
position matters when making decisions about risk, even among scientists and regulators. This finding 
indicates that social position is a relevant consideration when investigating how individuals perceive and 
communicate risk. 
1. In my company, we worry that nanotechnologies 
may encounter unwarranted public backlash such 
as that which accompanied genetically modified 
foods in Europe (67% agree).
2. Insurers in my industry are increasingly 
concerned about nano-specific risks (30% 
agree; 40% don’t know; 30% disagree).
3. Direct involvement of citizens in policy 
decisions about research and development of 
new technologies is beneficial (55% disagree).
Strongly agree Agree Disagree Strongly disagree
0% 20% 40% 60% 80% 100%
Don’t know
Figure 3.3. Industry concern about the public response. The study asked nanotechnology companies to rank 
their agreement with each of five statements on a scale of strongly disagree, disagree, don’t know, agree, and 
strongly agree. These results indicate that most companies are worried about public backlash and do not trust 
the public to be involved in policy decisions. (Figure courtesy of B. Herr Harthorn.) 
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The main point is that all stakeholders have motivated cognition that affects the way they engage in 
decision making. Therefore, biases need to be accounted for in a structured way, using explicit analytics 
for the decision-making process. Under development at CNS-UCSB is a nanotechnology risk screening 
tool [33] for structured decision making. Technical risk data alone will not affect decisions; judgments by 
different stakeholders with varying biases, values, and stances, and differing levels of power and 
interest, will also be involved. Overall, better outcomes will result if these issues are explicitly addressed. 
Figure 3.4. Expert perceptions of ENM risks and benefits. Scientists and regulators were asked to rank the 
relative risks and benefits of ENMs. Although the majority of experts agreed that the benefits will greatly 
outweigh the risks, nanotechnology scientists and engineers felt more strongly (60%) than regulators (27%) did 
in this regard. NSE: nanotechnology scientists and engineers, NEHS: nanotechnology EHS researchers, NREG: 
nanotechnology regulators. (Figure courtesy of B. Herr Harthorn.) 
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A Perspective from Industry (Microelectronics Business Perspective) 
Regulatory Challenges and Impacts on Carbon Nanomaterial Development 
Summary of Remarks by Stephen Gibbons, PhD  Director of Technology, Carbon Electronics Center Brewer Science, Inc. 
Brewer Science conducts research in, develops, and manufactures advanced materials and equipment 
for making devices used in microelectronics. The company’s core competencies are in materials 
innovation, design, manufacturing, and process integration, and its patent and commercialization 
portfolio includes supplying the first microelectronics-grade carbon nanotube (CNT) solutions on a 
commercial scale. 
Limited data exist for determining the EHS, regulatory, and business implications of nanotechnology 
products and processes. Brewer Science has investigated EHS impacts of nanomaterial release into air, 
water, and soil; impacts on both humans and wildlife; and environmentally friendly methods for the 
effective and efficient disposal of nanotechnology-related solid and liquid wastes. Newer approaches 
have involved gap analysis to determine what types of data are needed for the efficient risk 
management of CNTs. Potential gaps include the following: 
• Unknown baseline environmental exposures for various kinds of nanoparticles. 
• Lack of life cycle studies based on realistic scenarios for the microelectronics industry. 
• Lack of well-understood exposure limits. 
• Lack of differentiation between the hazards associated with different CNT chemistries [34]. 
The NNI agencies could help in several areas to support industry in responsible, effective, and profitable 
development of nanotechnology. First, they could help in terms of education. Second, they could help 
regulators to realize that different nanomaterials and different functionalizations of nanomaterials pose 
different potential risks. Third, given that many regulatory frameworks are based on theoretical models, 
due to a lack of conclusive EHS data, it would be extremely beneficial to have a widely accessible, 
searchable information repository on the EHS implications of various nanomaterials. Finally, the NNI 
agencies could help devise a consistent set of criteria with which nanomaterials can be assessed for EHS 
implications—criteria that should take into account life cycle analyses, nanomaterial volumes in 
consumer devices, and other relevant variables. 
A Perspective from the Consumer Community 
Summary of Remarks by Michael Hansen, PhD Senior Staff Scientist Consumers Union 
Products that contain nanomaterials are not sufficiently labeled, as demonstrated by results from the 
2008 Consumers Union test of commercial sunscreens ([35], see Figure 4.1 and Table 4.1). In a December 
2008 study, Consumer Reports tested five sunscreens containing titanium dioxide and zinc oxide. None 
of the products tested had a “nano” claim on its label, and when asked by Consumer Reports, customer 
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service representatives from five companies stated that 
each did not contain nanoparticles. Tests showed that 
nanoparticles were present, at least to a limited extent, 
in four out of the five products. Additionally, Consumer 
Reports tested one sunscreen that did make a nano 
claim on its label and found that it did contain 
nanoparticles. However, a customer service 
representative stated that the nanoparticles of titanium 
dioxide are coated with wax and thus cannot enter the 
skin. 
Although more risk assessment research is now being 
funded by NNI agencies, more work is needed 
concerning the detection of nanoparticles as they are 
functionalized in consumer products on the market. This 
will facilitate assessment of potential impacts on 
consumers in realistic exposure scenarios (once 
nanoparticles have been incorporated into the food or 
product matrix). Although toxicity and exposure testing using commercially available standardized 
nanoparticles is becoming more common, the available samples need to be better aligned with 
nanomaterials actually on the market, especially in products used on or in the human body. Further, all 
functionalized forms need to be looked at separately. The NNI website and NNI brochures need to be 
more user-friendly in terms of making it easier to find the research on hazard and risk assessment. 
Likewise, the good work by CPSC in the area of nanotechnology risk assessment [36] should be easier to 
find online. 
Table 4.1. Consumer Reports test results for the presence of nanoparticles in sunscreens (Reproduced from 
[35]) 
Product Nano claim Our findings 
Aubrey Organics Natural Sun SPF 25 
Green Tea Protective Sunscreen 
No. A company representative said the titanium dioxide is 
not in nano form.  
Yes 
Badger SPF 30 Sunscreen  No. A customer service representative said the product has 
micronized zinc that sits on the skin and is not absorbed. 
Yes 
California Baby SPF 30+ Sunscreen Yes. In its raw form the titanium dioxide is nano, but it is 
coated with waxes so that it does not enter the skin, a 
company representative said. 
Yes 
Kiss My Face SPF 30+ Sun Screen No. The product does not contain nanoparticles of 
titanium dioxide, a customer service representative said.  
Yes 
Mexitan SPF 30 Sunscreen  No. The titanium dioxide and zinc oxide used are not nano-
particles, according to a customer service representative. 
Yes 
Zinka Colored Nosecoat*  No. The product contains no nano, a customer service 
representative said. 
No 
None of the products tested had nano claims on its label. 
 *Zinka makes no SPF claim on the package. 
 The International Life Sciences Institute (ILSI) has initiated two “NanoRelease” projects, one themed 
“Consumer Products” [37] and one themed “Food Additives” [38], both of which aim to develop methods 
to detect nanomaterials in consumer products and in the human body following product use. The ILSI 
Figure 4.1. Image of six sunscreens tested by 
Consumer Reports for the presence 
nanoparticles. ©2008 by Consumers Union of 
U.S., Inc. Yonkers, NY 10703-1057, a nonprofit 
organization. The December 2008 study 
looked for the presence of nanoscale titanium 
dioxide and zinc oxide [35]. Reprinted with 
permission from the December 2008 issue 
of Consumer Reports for educational purposes 
only. No commercial use or reproduction 
permitted. 
   
 Stakeholder Perspectives on Perception, Assessment, and Management of the Potential Risks of Nanotechnology 
4. Plenary Presentations—Stakeholder Perspectives 17 
model is a good one in that these projects have broad participation from all sectors in their steering 
committees and are looking at items in actual commercial use. The ILSI studies are crucial from a 
consumer perspective because there are so few studies on detecting nanoparticle uptake in the human 
digestive system. If you can’t detect the nanoparticle, you can’t measure exposure or determine risk. 
The current regulatory framework is not sufficient for assessing the risks of nanotechnology-enabled 
consumer products, especially for nanoparticles that are actually in use in cosmetics, foods, food 
additives, etc. In April 2012, FDA released two draft guidance documents [39, 40]. Both included 
consideration of deliberately manipulated materials up to 1000 nm in size. The first document, which 
addresses food additives, states that ENMs “likely would not be covered” by existing “generally 
recognized as safe” (GRAS) standards, making these materials subject to formal premarket review 
[39]. The second document, covering cosmetics, suggests that industry should revise its safety testing 
using a “tiered testing” approach due to the unique properties of ENMs [40]. FDA has no authority to 
require premarket testing for cosmetics under the Federal Food, Drug, and Cosmetic Act (FFDCA), and 
FDA assumes the existing battery of tests are “probably adequate” for testing of ENMs. A bill called the 
Safe Cosmetics and Personal Care Products Act of 2013 [41, 42] has been introduced in the U.S. Congress 
that would give the FDA the regulatory authority to require testing and labeling of ENMs in cosmetics. 
The Environmental Protection Agency (EPA) Nanoscale Materials Stewardship Program (NMSP) [43] has 
released an interim report on the NMSP indicating that 90% of likely commercially available nanoscale 
materials are not reported by companies at all [44]. This low rate of engagement suggests that 
companies are not inclined to voluntarily test their nanomaterials, and efforts in the UK and Denmark to 
utilize voluntary reporting schemes have also proven unsuccessful. Mandatory approaches are needed. 
France requires industry reporting of the identity, quantity, and uses of ENMs. Canada has a mandatory 
safety reporting system for import and production of ENM amounts greater than one kilogram. 
EPA has authority over ENMs under the Toxic Substances Control Act (TSCA). However, standard 
toxicology testing for ENMs is not based on volume or quantity but on surface area, making the low-
volume and low-release/low-exposure exceptions1 inappropriate for nanoscale materials. Consequently, 
these exemptions need to be reconsidered for ENMs. EPA has thus attempted to recognize that 
nanoscale materials may pose different risks than bulk-scale materials in its regulations. In 2011, EPA 
promulgated significant new use rules (SNURs) [45] under TSCA [46] for multiwalled CNTs. Subsequently, 
EPA has proposed SNURs for 37 other chemicals, including 14 nanomaterials [47]. While these SNURs are 
being reviewed by the Office of Management and Budget (OMB)2 [48], EPA has begun product-by-
product data call-in notices for nanosilver products under the Federal Insecticide, Fungicide, and 
Rodenticide Act (FIFRA) section 3(c)(2)(B)[49]. 
Since ENMs are different than bulk materials, the U.S. Government should mandate testing and 
reporting to determine how much is in use and develop protocols, even if just to find that ENMs are not 
problematic. 
                                                          
1 Chemical substances manufactured in quantities of 10,000 kg or less per year and chemical substances with low environmental 
release and human exposure, 40 C.F.R. §723.50 (2012). 
2 On February 25th, 2013, EPA announced Proposed Significant New Use Rulings (SNURs) for 37 chemical substances, including 14 
substances whose reported chemical names include the term “carbon nanotube” or “carbon nanofibers.” These rules became final on 
September 2, 2014, for 36 of those substances, including all of the nanomaterials. An additional set of SNURs for 52 chemical 
substances, including one nanomaterial (functionalized carbon nanotubes generic PMN No. P-13-793), was promulgated on October 
27th, 2014. This SNUR was partially withdrawn for 30 of these chemicals (including PMN No. P-13-793) on December 23rd, 2014, 
because EPA received a notice of intent to submit adverse comments. 
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A Perspective from the Labor Community 
Assessment and Management of the Potential Risks of Nanotechnology 
Summary of Remarks by Darius Sivin, PhD Health and Safety Department International Union, United Auto Workers 
Our ability to measure, manipulate, and process at the nanoscale is new. The United Auto Workers 
(UAW) is concerned that the lack of data regarding ENMs could present problems for auto workers. This 
includes potential hazards of exposure and the ability of workers to know which materials are present in 
specific products they handle. The Occupational Safety and Health Administration (OSHA) Hazard 
Communication Standard (i.e., the “right-to-know standard”) requires manufacturers who sell materials 
utilized in the workplace to provide “safety data sheets” (SDSs) to employers [50]. These SDSs provide 
information about the material composition and potential hazard(s) of each component. Employers are 
then required to train and inform their workers regarding what potential hazards exist in the work 
environment in order to minimize any risk of exposure associated with such hazards. One problem is 
that in the OSHA regulation an “article” is exempt from reporting requirements.3 
“Articles” are typically manufactured products, such as an engine or a dashboard, that arrive at a factory 
as a unit, the assumption being that they will not be further processed.4 However, articles often require 
physical modifications (i.e., grinding, cutting, or buffing the material) to ensure that they fit properly, 
thereby creating new opportunities for hazard exposure in the absence of potential hazard information 
(for example, what the articles are coated with). 
Another problem is that SDSs are 
often incomplete ([51], Figure 
4.2). The Hazard Communication 
Standard does not clearly indicate 
whether a manufacturer or 
distributor is responsible for 
indicating that a material is a 
nanomaterial. The chief science 
advisor for the Project on 
Emerging Nanotechnologies, Dr. 
Andrew Maynard, stated that 
“carbon nanotubes are as similar 
to pencil lead as the soot on my 
grill at home is to diamonds” [52]. 
One review of SDSs by the Lippy 
Group revealed that 33% of these 
sheets failed to identify a 
nanoscale component as present 
and that 52% did not include any cautionary language [53]. Furthermore, the National Institute for 
Occupational Safety and Health (NIOSH) performed a review of 26 SDSs that revealed that 58% of the 
documents contained occupational exposure limits (OELs) for the bulk material without providing 
                                                          
3 Hazard Communication, 29 C.F.R. §1910.1200(b)(6)(v) 
4 Hazard Communication, 29 C.F.R. §1910.1200(c) 
Figure 4.2. An example of a safety data sheet (SDS) using an inappropriate 
synonym for a nanomaterial. This safety data sheet for carbon nanotubes 
uses the 15 mg/m3 nuisance dust standard for synthetic graphite [51]. 
(Figure courtesy of D. Sivin.) 
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guidance that the OELs may not be appropriate for the nanoscale material. Overall, 69% of the 26 sheets 
were classified as “in need of serious improvement,” and none were classified as “good” [54]. Ultimately, 
documentation practice does not adequately communicate the potential for nanomaterial exposure 
among workers in the automotive industry; thus, it does not allow workers or the union to know the 
possibilities for nanomaterial exposure. As such, the union cannot encourage employers to take 
appropriate precautions, despite the highly developed occupational safety and health programs that are 
jointly administered by the union and the big three auto manufacturers. This problem is compounded 
when more and more work is outsourced to owner-run suppliers with less knowledge, ability, and on-
site staff to address possible ENM hazards. 
How do we address the lack of data about ENM hazards? A lesson learned from the petrochemical 
industry experience is that regulatory regimes must be devised early on to adequately distinguish 
between beneficial and harmful technologies and be able to restrict harmful ones before exposure is 
widespread. We need to be willing to act on incomplete knowledge to protect people. Control banding, 
which incorporates Lawrence Livermore probability and risk severity scores, is one promising method for 
risk assessment in the face of incomplete information and uncertainty [55]. 
In summary, we need more information about which products contain what nanomaterials. In addition, 
improved risk communication is necessary to mitigate the “where” and “when” of worker exposure to 
nanomaterials. This goal can be accomplished in part through full disclosure of nanomaterial safety 
information in SDSs. Suppliers and employers can assist in this effort by tracking who is exposed to 
nanomaterials and when exposure can potentially occur. And we need to learn from past mistakes and 
be more proactive about instituting some level of protection while data are still being acquired. 
A Perspective from the Standards Community 
The Role of Standards in Addressing Issues Relating to Risk and Nanotechnology 
Summary of Remarks by Ajit Jillavenkatesa, PhD Senior Standards Policy Adviser, Standards Coordination Office National Institute of Standards and Technology 
Standards provide confidence in the efficacy of tools used to assess and mitigate the potential risks of 
nanotechnology. However, they are only as good as the community’s engagement in their development, 
in their use, and in publishing both successes and failures. “Documentary standards” are composed of 
agreed-upon and documented principles, approaches, and tests established by consensus and approved 
by a standards development body [56]. Such standards are generally formed by experts on the basis of 
sound scientific data. Regulators sometimes choose to refer to these standards for guidance. 
Standardized approaches are very important in assessing risk. They enable clarity in communication, 
which enables the protection of human and environmental interests when used by regulators. Standards 
are also important for technology innovation, allowing developers to work on common platforms or 
foundations that are established by these standards. Finally, when standards are harmonized on a global 
scale they facilitate communication and trade among stakeholders and provide broad benefit. 
Standardization activities relevant to the nanotechnology risk management process are being developed 
in a wide range of standards organizations. ASTM International [57] and the International Organization 
for Standardization (ISO) [58] are two such organizations with significant efforts relating to 
nanotechnology standards development. Efforts in three major areas worth noting relate to 
terminology, measurement, and EHS characterization (see Table 4.2). Both of these organizations 
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develop standards using open, transparent, consensus-driven processes involving multiple stakeholders 
to develop terminology, characterization, and measurement guidelines to assist EHS research and risk 
management for nanotechnology [59]. A standards document on general risk management principles 
has also been published [60]. Several documentary standards resources are the Nanotechnology 
Standards Database, sponsored by the American National Standards Institute (ANSI) Nanotechnology 
Standards Panel [61]; the ISO online browsing platform [62], which provides access to standards 
documents; the Nanomaterial Registry [63]; Germany’s Federal Institute for Materials Research and 
Testing (BAM) Nanoscale Reference Materials [64] website, and a Nanostandards Wiki [65]. 
Table 4.2. Illustrative examples of documentary standards available for nanomaterials (current at the time 
of the workshop, and subject to revision and updates) 
For effective standardization, several questions must be considered and addressed: 
• What needs to be standardized? 
• By when is it needed? 
• Are there priorities for certain standards? 
• Are there good data on which to base the standards? 
• Is there a consensus on techniques? 
Type of 
Standard Unique Identifier Title 
Terminology ASTM E2909-13  
Standard Guide for Investigation/Study/Assay Tab-Delimited Format 
for Nanotechnologies (ISA-TAB-Nano): Standard File Format for the 
Submission and Exchange of Data on Nanomaterials and 
Characterizations [66] 
 ISO/TS 80004-1:2010  Nanotechnologies -- Vocabulary -- Part 1: Core terms [67] 
 ISO/TR 14786  Nanotechnologies -- Considerations for The Development of Chemical Nomenclature for Selected Nano-objects [68] 
 ISO/TS 80004-3:2010  Nanotechnologies -- Vocabulary -- Part 3: Carbon Nano-objects [69] 
Measurement ASTM E2578 - 07(2012)  
Standard Practice for Calculation of Mean Sizes/Diameters and 
Standard Deviations of Particle Size Distributions [70] 
 ASTM E2864-13 
Standard Test Method for Measurement of Airborne Metal and 
Metal Oxide Nanoparticle Surface Area Concentration in Inhalation 
Exposure Chambers using Krypton Gas Adsorption [71] 
 ISO/TR 13014:2012  Nanotechnologies -- Guidance on Physico-Chemical Characterization of Engineered Nanoscale Materials for Toxicologic Assessment [72] 
 ISO/TS 14101:2012  Surface Characterization of Gold Nanoparticles for Nanomaterial Specific Toxicity Screening: FT-IR Method [73] 
EHS Effects ASTM E2535-07(2013)  Standard Guide for Handling Unbound Engineered Nanoscale Particles in Occupational Settings [74] 
 ASTM WK 34427 New Guide for Nanotechnology Workforce Education in Health and Safety (under development) [75] 
 ISO/TR 13121:2011  Nanotechnologies -- Nanomaterial Risk Evaluation [76] 
 ISO 10808:2010  Nanotechnologies -- Characterization of Nanoparticles in Inhalation Exposure Chambers for Inhalation Toxicity Testing [77] 
 ISO/TS 12901-1:2012  
Nanotechnologies -- Occupational Risk Management Applied to 
Engineered Nanomaterials -- Part 1: Principles and Approaches [78] 
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• How will the standards be used? 
• Will the community participate in the validation and adoption of the standards? 
Certain guidance can be gained by referencing past successes and failures from other sectors, including 
the experiences of the information security and financial industries, among many others. Inputs from all 
stakeholder groups should inform and support the process of creating standards; their continual 
engagement is essential for effective standardization. 
A Perspective from the Regulatory Community 
Assessment and Management of Nano Risk: A Regulatory Perspective 
Summary of Remarks by Tim Malloy, JD Professor of Law; Faculty Director, Sustainable Technology and Policy Program University of California, Los Angeles 
Regulations should follow the principles of transparency, flexibility, pragmatism, consistency, and rigor, 
with the ultimate goal of being protective. Other than direct regulation by the Federal Government or 
States, there are other, less-examined, ways of regulating risk. The first is a more decentralized 
mechanism, tort liability. The NNI might want to further examine this mechanism. Torts are civil wrongs 
that place the regulation of risk in the hands of the judicial system. Information disclosure is another 
way of regulating risk, such as in the form of SDSs. There are also more direct regulatory mechanisms; 
for example, at the Federal level, EPA manages CNTs in a new chemical program under TSCA [79], and 
the review of food additives by FDA may result in the regulation of nanomaterials [80]. 
California has been very active with respect to nanotechnology-related information disclosure. One 
California statute allows the State’s Department of Toxic Substances Control (DTSC) to obtain 
information about nanomaterials from manufacturers.5 However, limited information has been obtained 
regarding the production volume of these nanomaterials, their application, and risk assessment and risk 
management practices. Although the statute does provide DTSC with the power to require 
manufacturers to develop analytical detection methods, such power has not been exercised to its full 
extent. 
In terms of direct regulation, most regulations are composed of four steps: 
1. Identify the product or process of concern. 
2. Prioritize the potential hazards. 
3. Assess the risk. 
4. Manage the risk. 
In California, the “Safer Consumer Products Regulation” [81] process is similar yet different in the two 
steps related to assessing and managing risk (steps 3 and 4). In Step 1, a “chemical of concern” is 
identified if a material exhibits what is known as a “hazard trait,” one of which is particle size or fiber 
dimension at the nanoscale. After the chemical or process of concern has been identified and has 
undergone prioritization (Step 2) instead of the classical risk assessment in Step 3, a “comparative risk 
assessment” is performed (also called an “alternatives analysis”). This assessment compares the product 
with alternative functionalizations, non-nanoscale versions, or other substitutes to determine if there is 
a safer alternative to the “chemical of concern.”6 The product under consideration and the alternatives 
                                                          
5 Cal. Health & Safety Code §§57018-57020 (2007) 
6 Safer Consumer Products Regulation, Cal. Code Regs. tit. 22, § 69505-69509 (2013) 
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are evaluated using a ranking system in light of major criteria reflected in the statute, such as the human 
health impact, ecological impact, environmental impact, technical performance, and economic impact of 
the product.7 This process requires regulators to identify materials of concern and to prioritize the risks 
presented by these various materials. Some resources that address these issues are provided in Table 
4.3. This approach might be better than quantitative risk assessment because a classical risk assessment 
is often viewed as being too data dependent or driven by hidden assumptions. Step 4 is also approached 
differently than in a quantitative process because the preference is for inherent protection rather than 
managing risk by controlling exposure. 
Regulatory agencies may encounter structural and administrative constraints when implementing 
regulations. They often face limitations with respect to funding, staff expertise, and collection of the 
right information. These limitations must be taken into account when designing and selecting a 
regulatory structure for nanotechnology risk management. 
Table 4.3. Resources for alternatives risk analysis 
A Perspective from the NGO Community 
A GreenScreen™ Hazard Assessment Approach for Nanomaterials—Nanosilver Case Study 
Summary of Remarks by Jennifer Sass, PhD Senior Scientist, Health and Environment Program Natural Resources Defense Council 
A novel tool called GreenScreen™ [87] can be used to screen and communicate hazard information on 
specific classes of nanomaterials in the face of missing data. It can be used to make informed decisions 
with respect to material selection, to encourage transparency with respect to the EHS implications of 
new materials, and to ultimately help decision makers move toward the adoption of safer technologies. 
This tool is free and publicly accessible, transparent, and peer reviewed, ultimately providing a 
standardized framework that can be used to conduct a comparative chemical hazard assessment. 
GreenScreen helps to facilitate alternatives analysis by providing a screening measure in the face of data 
gaps, but the tool does not generate new data. Instead, it uses data that are already available and 
substitutes for missing data when certified profilers believe that this substitution can be performed 
scientifically. The certification of profilers ensures the operational credibility of the tool. 
                                                          
7 Safer Consumer Products Regulation, Cal. Code Regs. tit. 22, § 69505.5-69505.9 (2013) 
Purpose Title 
Identifying materials of concern, 
their uses, and their fate 
Global life cycle releases of engineered nanomaterials (2013) [82]  
 Modeling approaches for characterizing and evaluating environmental 
exposure to engineered nanomaterials in support of risk-based 
decision making (2013) [83]  
Prioritizing materials of concern Risk-based classification system of nanomaterials (2009) [84]  
 The use of Bayesian networks for nanoparticle risk forecasting: Model 
formulation and baseline evaluation (2012) [85]  
Evaluation of an approach for 
conducting the alternatives analysis 
Use of multi-criteria decision analysis in regulatory alternatives 
analysis: A case study of lead free solder (2013) [86]  
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The GreenScreen assessment is based on 18 environmental and human health endpoints, which are 
divided into four categories: two categories for human health hazards, one for environmental toxicity 
and fate, and one for physical hazards. These endpoints include carcinogenicity; genotoxicity; endocrine 
disruption; reproductive toxicity; and persistent, bioaccumulative, and toxic (PBT) effects [88]. If a 
material ranks highly in any of these categories, it is labeled “highly toxic,” following the same model as 
the European Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) program 
[89]. The process also includes a life cycle analysis by examining the constituents and breakdown 
products that emerge during processing, manufacturing, or disposal. Based on the overall assessment, 
GreenScreen provides an overall benchmark score that supports a course of action [90]. 
The tool can be used to help individuals who are not toxicology experts to make product design and 
regulatory decisions. For example, GreenScreen is used by a number of organizations, including the EPA 
Design for the Environment program; the U.S. Green Building Council; and companies in the private 
sector, including Hewlett-Packard, Staples, and IBM. Several State regulatory agencies also use 
GreenScreen; for example, the tool will be used in the implementation of the California “Safer Consumer 
Products Regulation” [81]. 
GreenScreen was used to assess nanoscale silver materials. Nanosilver was selected due to its known 
stability in various environments and media, as well as its potential for release in consumer products. 
The GreenScreen analysis included a comparison of (1) conventional silver (low-solubility dispersed non-
nanoscale silver and silver salts), (2) nanoscale metallic silver, and (3) a nanoscale silica-silver composite. 
The decision to test conventional silver was informed by stakeholder inputs; the release of silver ions 
from the selected nanomaterials could be considered a source of toxicity, and because conventional 
silver also releases silver ions, it served as a control. 
The GreenScreen results for nanosilver indicate that with respect to judging acute inhalation hazards, 
the structural form is a critical factor to consider. These material assessments are discussed on the 
Jennifer Sass blog [91] and in other documents [92]. Researchers can use GreenScreen to facilitate safer 
design approaches, enable hazard screening before humans or the environment are exposed to 
nanomaterials, and identify crucial data gaps. 
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5. Breakouts—Approach and 
Charge to Participants 
Approach to the Breakout Sessions 
The purpose of the parallel breakout sessions held on Day 1 and Day 2 was to gather inputs on tools, 
methods, and practices that support risk-based decision making for various types of decisions and by 
various communities of decision makers. Considering a product life cycle approach ([93, 94], Figure 5.1), 
the breakout groups were organized in two ways: 
• Day 1: Breakouts by Decision Type to gather inputs from the perspectives of three different 
frameworks in which decisions are made: occupational risk analysis, the commercial product life 
cycle, and the environmental life cycle. 
• Day 2: Breakouts by Decision-Maker Community to gather inputs from each of seven types of 
stakeholder communities, loosely defined as follows: 
o Research community: academia, national laboratories, research institutes, and intramural 
government research facilities. 
o Regulatory community: Federal regulatory agencies, State and local governments, 
multinational organizations (e.g., the European Union and the Organisation for Economic 
Cooperation and Development), and lawyers. 
o Nanomanufacturers: primary manufacturers of engineered nanomaterials (ENMs), 
manufacturers of nanotechnology-enabled products, the military, and trade associations. 
o Small business: start-ups and businesses with less than 50 employees. 
o Financial risk community: insurance agencies, venture capitalists, and lawyers. 
o NGO community: consumer and environmental protection groups and other public interest 
groups. 
o Other public communities: consumers, nanotechnology production workers, labor unions, 
and the collective public. 
Figure 5.1. Product life cycle showing different points for EHS evaluation. (Source: 2014 NNI Strategic Plan 
[94], adapted from [93].) 
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Breakout Session Structure 
The breakout sessions on both days were composed of two parts: (1) an introduction involving a real-
world case study to provide background and a working framework for participants, followed by (2) an 
exercise involving a theoretical vignette. 
Real-World Case Study 
The session co-chairs were asked to provide a practical/real case example relevant to nanotechnology 
risk management and what approach/solution they had adopted in their consideration of risk. 
Specifically, they were asked to discuss the tools or methods that they had adopted when handling the 
case and the solutions that they had developed as a result. Participants were encouraged to share as 
much real-world experience as possible to move beyond generic discussions of risk analysis and towards 
navigating actual situations and knowledge gaps. After the case study was discussed by the group, the 
co-chairs led participants through an interactive study of the theoretical vignette. 
Theoretical Vignette Exercise 
The vignette exercise aimed to focus the discussion and elicit concrete, fact-driven information relating 
to real-world experiences. Used in all of the breakout sessions on both days, the exercise was developed 
with the following criteria in mind: 
• The vignette should be general enough so that it does not implicate a specific individual, 
organization, product, or material. 
• The vignette should present the potential for the release of a material and, therefore, an 
opportunity to consider fate, exposure, and toxicity. 
• The vignette should have applications that all participants can relate to easily. 
• The vignette should involve an application, not just a specific nanoparticle. 
• There should be compelling societal benefits as well as potentially serious risks associated with 
the application/nanoparticle. 
Based on these criteria, the following vignette was presented to breakout session participants to be 
considered in the context of their stakeholder community: 
Nanoparticle X is a new nanoparticle that is being produced by several companies and added 
to drywall and paints to provide excellent energy-saving insulating properties. It is also being 
considered in food packaging to keep foods cold on the shelf and in blood bags to preserve 
donated blood. It is sold as a powder that is stirred into paint or added to thermoset 
polymers for packaging. One rat inhalation study of a similar but slightly different particle 
found a considerable increase in lung tumors in exposed animals. Some companies have 
added a proprietary functional group to the particle or encapsulated the particles in an effort 
to minimize the compound’s reactivity. The discrete nanoparticle is highly reactive, but 
becomes very stable in cured polymer matrices. Durability of its insulating properties reflects 
the properties of the matrix, so that it is potentially released when the end product 
degrades. 
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The stakeholder and decision-type communities were then asked to use their experiences in their 
various roles in nanotechnology development to answer the same four questions with regards to the 
vignette. The four thematic questions were as follows: 
A. What types of risk assessment processes, if any, are being used in decisions about the 
commercialization/development/use of Nanoparticle X? 
B. What are the tools/approaches/models and information needed for risk assessments and risk-based 
decision making? 
C. How are risk information and uncertainty factored into the decision? 
D. How can the NNI best support risk-based decisions? 
Breakout Reports 
After each day of breakouts, the breakout co-chairs provided a report to the main group on the results 
of their discussions. The goal was to gather each group’s perspective on approaching risk, including risk-
based questions, decisions to be made, relevant tools and methods, and decision drivers, and then to 
compare those inputs across the various breakout groups to identify commonalities in processing risk-
based information. 
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6. Breakouts Focused 
by Decision Type 
The first set of breakout sessions focused on the types of decisions made when approaching the 
potential risks of nanotechnology. Stakeholders were split into three concurrent sessions addressing the 
following decision frameworks: (1) occupational risk analysis, (2) the commercial product life cycle, and 
(3) the environmental life cycle. Each group began with a presentation from the co-chair(s) on a real-
world case study related to the breakout framework. Following this, all groups were asked to work 
through the same hypothetical “vignette” in the context of the session framework and were charged 
with answering four discussion questions, as noted in Chapter 5. The discussions are summarized below. 
Group 1: Occupational Risk Analysis and Decision Making 
Co-Chairs:  Paul Schulte, PhD, National Institute for Occupational Safety and Health Bruce Lippy, PhD, CPWR—The Center for Construction Research and Training 
Occupational Risk Framework 
The co-chairs noted that the data gaps associated with emerging technologies have presented a 
significant challenge with respect to risk-based decision making and that what little is known must be 
used to make decisions to protect workers at all stages of the product life cycle. In the case of 
“Nanoparticle X,” a number of assumptions must be made throughout the risk management process due 
to a lack of information. The co-chairs made several general points during the case study discussion: 
• The hierarchy of controls, which has been a guiding principle for industrial hygiene, has been 
recommended as a model for nanoparticle control in most international guidance. 
• Hazard and control banding tools can assist nanotechnology-related risk management in the 
occupational context. One example is the “Control Banding Nanotool” ([55], Figure 6.1). 
Severity Probability 
 
Extremely 
Unlikely 
(0–25) 
Less Likely 
(26–50) 
Likely 
(51–75) 
Probable 
(76–100) 
Very High 
(76–100) 
RL 3 RL 3 RL 4 RL 4 
High 
(51–75) 
RL 2 RL 2 RL 3 RL 4 
Medium 
(26–50) 
RL 1 RL 1 RL 2 RL 3 
Low 
(0–25) 
RL 1 RL 1 RL 1 RL 2 
Figure 6.1. Example of the control banding nanotool. Risk is calculated as the severity of the hazard scaled by 
the probability of exposure. The red cells show the highest risk (RL 4), and the green cells show the lowest risk 
(RL 1). (Redrawn with permission of the authors from Paik et al. Application of a Pilot Control Banding Tool for 
Risk Level Assessment and Control of Nanoparticle Exposures. Ann Occup Hyg (2008), and reprinted by 
permission of Oxford University Press on behalf of the British Occupational Hygiene Society [55].) 
Key to Risk Levels 
RL 1: General 
ventilation 
 RL 2: Fume hoods 
or local exhaust 
ventilation 
 RL 3: Containment 
RL 4: Seek specialist 
advice 
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• Many nanomaterials, due to their effectiveness and high performance in a product, are unlikely 
to be eliminated or substituted by manufacturers without clear evidence that the materials pose 
a hazard. As an alternative to substitution, the National Institute for Occupational Safety and 
Health has demonstrated that engineering controls can be an effective way of managing risk 
with nanomaterials ([95]; see also Figure 6.2). Control methods to ensure industrial hygiene are 
listed in decreasing order of preference based on effectiveness: elimination, substitution, 
engineering controls, warnings, administrative controls, and personal protection. For example, 
CPWR—The Center for Construction Research and Training—has demonstrated that ventilation 
can be an effective engineering control for worker safety when handling construction 
nanomaterials [96]. 
 
Figure 6.2. CPWR demonstrates the effectiveness of ventilation with construction nanomaterials. Here, a 
worker using a tile cutter on a clay roofing tile and producing a large amount of clay dust (on the left) can 
control exposure using a fitted vacuum hood (on the right). (Images courtesy of B. Lippy.) 
Vignette Discussion 
A. What types of risk assessment processes, if any, are being used in decisions about the 
commercialization/development/use of Nanoparticle X? Initially, breakout session participants 
discussed many technical decisions that must be made when undertaking risk assessment, including 
determining the appropriate sampling strategies and equipment, specifying the toxicological studies 
that are needed, and assessing how much value can be assigned to data on analogous materials. 
Furthermore, participants suggested beginning the risk assessment process by asking who is being 
exposed and whether a product contains nanoparticles. 
B. What are the tools/approaches/models and information needed for risk assessments and risk-based 
decision making? A number of approaches and tools were discussed: 
• The REACH program approach to nanomaterials, initiated through European legislation [89]. 
• The collaborative approach of the Nano GO Consortium [97]. 
• Qualitative risk assessment, serving as a key approach for testing a great number of ENMs, given 
data limitations. 
• The “Good Nano Guide,” serving as an “Internet-based collaboration platform for experts to 
exchange ideas on handling nanomaterials in an occupational setting” [98]. 
• Agency publications from NIOSH [99]. 
C. How is risk information and uncertainty factored into the decision? Some industry representatives 
discussed whether the business risk of using nanoparticles could be justified. Uncertainty may lead 
decision makers to err on the side of caution. 
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D. How can the NNI best support risk-based decisions? Participant suggestions included the following: 
• Coordinate ongoing meetings with non-Federal stakeholders to discuss their needs and risk 
management approaches. 
• Provide information about the risks directly to non-Federal stakeholder groups. 
• Coordinate among NNI member agencies to disseminate key data and to facilitate an 
understanding of the agencies’ respective roles. 
• Support research on baseline environmental levels for key ENMs. 
• Work with State governments to help to develop approaches for risk management. 
• Facilitate the development of inventories (e.g., an inventory of SDSs). 
• Support efforts to determine how intellectual property regulations are impacting EHS 
information collection and dissemination. 
Group 2: Commercial Product Life Cycle 
Co-Chairs:  Rick Canady, PhD, International Life Sciences Institute (ILSI)  Todd Kuiken, PhD, Woodrow Wilson International Center for Scholars 
Commercial Product Life Cycle Stage Framework 
The co-chairs focused on the risk of nanomaterial exposure from food packaging, referencing a 2008 
study from the Wilson Center [100]. They suggested that a life cycle approach is important in this context 
because ENM introduction can occur during different life cycle stages, including handling, processing, 
packaging, ingredient introduction before and after processing, and intake/consumption. Considering 
these aspects, they reviewed the three hypothetical case studies in the 2008 report to help to identify 
regulatory and scientific needs to frame the breakout session discussion. The case studies in the 2008 
report were the following: 
• Case 1: A nanoscale sanitizer that prevents the contamination of packaging film used to wrap 
fresh produce or meat. 
Although the outside surface of this film is a conventional material, the inside (the food contact 
surface) is an ultrathin layer of nanoparticles functionalized as microbial inhibitors. 
• Case 2: A packaging film that detects and quantifies microbial pathogens in products as they 
move through the food-processing chain. 
This nanobiosensor is based on enzyme-linked immunosorbent assay (ELISA) technology and is 
incorporated into the inner (food contact) surface. 
• Case 3: Barrier packaging for carbonated beverages. 
The barrier material, used to prevent the permeation of water vapor, oxygen, and CO2, has an 
inner layer of polypropylene embedded with nanoclay particles and sandwiched between 
conventional polyethylene layers. 
In the 2008 study, each case was run through a mock regulatory submission to the Food and Drug 
Administration and the Environmental Protection Agency to determine if (1) the regulations seemed to 
be addressing the right issues, and (2) where science and methods could fill information gaps. The 
Wilson Center report contributed to the FDA guidance, adding language to call for data on particle 
characteristics and to clarify the relevance of existing data for evaluating the “generally recognized as 
safe” (GRAS) status of nanoscale materials. 
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Vignette Discussion 
A. What types of risk assessment processes, if any, are being used in decisions about the 
commercialization/development/use of Nanoparticle X? Session participants discussed possible 
information gaps in assessing the risks posed throughout the course of the commercial product life 
cycle. They identified “who is being exposed to the ENM?” and “how is that exposure occurring?” as 
two central pieces of information that would be needed (Figure 6.3). When discussing factors 
affecting the success of risk-based decision making, some participants noted that the efficacy of risk 
communication and perception is critical because effective risk communication and perception help 
to align actual risk and perceived risk. They also identified the quality and reliability of available data 
as fundamental issues. 
B. What tools, approaches, models, and/or information are needed for risk assessments and risk-based 
decision making? Both GreenScreen [87] and presubmission consultation with the FDA [101] were 
suggested as important tools, in addition to the nanotechnology-specific databases that are 
available, including the Nanomaterial Registry [63] and the publications database available at 
nanoHUB [102]. Some participants also cited PubMed [103] and other non-nanotechnology-specific 
databases as sources of information that may be relevant to risk assessment in this context. 
C. How are risk information and uncertainty factored into the decision? Some participants named 
analytical techniques such as “fuzzy set theory” and structured decision making (SDM) as helpful in 
allowing decision makers to account for risk in the face of uncertainty, as well as guidance 
documents provided by organizations such as FDA [104]. Value-of-information analysis was cited as a 
tool to “quantify…the potential benefit of additional information in the face of uncertainty” [105]. 
Participants also discussed methods of communicating risk and uncertainty to decision makers: 
• Control banding, which is used “to guide the assessment and management” of risks [106], can 
assist in communicating risk and uncertainty to decision makers by providing a visual guide. 
• Risk information should be conveyed to decision makers in a way that allows them to engage in 
responsible governance. For example, researchers and developers should share relevant 
information to fill data gaps and should explain the robustness of the available data. This will 
help decision makers to understand the extent and causes of uncertainty for ENMs. 
D. How can the NNI best support risk-based decisions? 
• A lack of agreed-to methods to measure nanomaterials in exposure conditions was identified as 
a key gap that affects safe product development. The co-chairs proposed specific support to 
methods development targeted at decision steps in a risk evaluation as a practical approach. For 
example, Figure 6.3 was presented as a decision sequence for which specific methods 
development could simplify product formulation and risk assessment approaches. 
• Some participants felt that NNI support could assist risk-based decision making by coordinating 
the identification of data and information gaps. They noted the following data gaps: exposure 
occurrence, exposure effects, ENM behavior before and after exposure, the presence of 
nanomaterials in existing products and environments, and the effects of regulatory responses. 
• It was suggested that the NNI also could facilitate the communication and dissemination of 
existing studies by supporting the development of inventories or repositories of information. In 
addition to a repository of EHS-related studies on nanomaterials (including both positive and 
negative results), an inventory of nanomaterial use could be created that keeps track of how 
certain nanomaterials are being used and implemented by consumers and industry, and how 
much of the nanomaterial is being used in each of these applications (e.g., the Wilson Center’s 
“living” consumer products inventory [107]). 
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Group 3: Environmental Life Cycle Implications 
Co-Chairs:  Tom Seager, PhD, Arizona State University Matthew Hull, PhD, Virginia Tech 
Environmental Life Cycle Implications Framework 
The co-chairs framed the vignette in terms of a life cycle assessment framework that could be used to 
assess the potential EHS risks of emerging technologies. They began by explaining that traditional tools 
used to perform life cycle assessments are primarily retrospective, as they rely on data gathered from 
commercial applications. However, risk-based data are often unavailable for emerging technologies due 
to the short time they have existed and the limited scale at which they have been implemented. 
To address this problem, Dr. Seager presented a life cycle assessment framework that assesses the EHS 
implications of a technology when data are sparse (see Figure 6.4). Despite uncertainty in many areas, 
this model can help to scale down data requirements for the risk management of emerging 
technologies. 
Figure 6.3. Hypothetical decision sequence for nanoparticle uptake assessment to prioritize data needs or to 
aid product development. There is an inverse relationship between the relative proportion of ENMs in 
commerce and the need to apply nanoparticle-specific toxicity tests. Ideally, products should be designed that 
have less need for specific toxicity tests. Product design and data needs depend on whether an ENM is 
persistent to the point of ingestion and on the behavior of the ENM after ingestion. (Figure courtesy of T. 
Kuiken.) 
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Dr. Hull focused on the environmental life cycle issues posed by the production of metallofullerenes via 
arc discharge. A recent study showed that leachate prepared from the soot from metallofullerene 
production was toxic to EPA test organisms due mainly to the release of copper [108]. Engaging industry 
is important to identify priority areas of research for life cycle risk assessment. Several takeaways from 
this case study are as follows: 
• Attention should be given to assessing the EHS risks presented by the manufacturing byproducts 
of engineered nanomaterials. 
• Life cycle assessments of manufacturing processes should be conducted as manufacturers 
increase the scale of their endeavors to meet increased demand. 
• More data on industrial activities must be gathered in order to advance environmental life cycle 
assessment research. 
• Rules and regulations must be made clear so that manufacturers are aware of the applicable 
requirements in this arena. 
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Figure 6.4. Life cycle assessment framework for emerging technology. This framework helps to facilitate life 
cycle assessment when data are sparse. The core of this framework is linear and traditional, comprising the 
extraction and benefaction, manufacturing, product use, and end-of-life processing stages of the life cycle. Not 
much research has been performed on manufacturing byproducts (yellow circle on the upper right). aLCA: 
abridged life cycle analysis. (Figure courtesy of T. Seager.) 
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Vignette Discussion 
A. What types of risk assessment processes, if any, are being used in decisions about the 
commercialization/development/use of Nanoparticle X? Breakout participants commented that the 
types of decisions made about risk are often dictated by the information required by regulatory 
agencies. Furthermore, some industry representatives explained that decisions made in regard to 
market entry involve risk, given that evaluating the potential commercial applications of a 
nanomaterial involves an estimate of its market acceptance and potential based on product 
performance. 
B. What are the tools/approaches/models and information needed for risk assessments and risk-based 
decision making? Several tools and approaches were discussed, including the following: 
• The Swiss Precautionary Matrix for Synthetic Nanomaterials is a tool “made to support all 
interest groups having a responsibility for the safety of workers, consumers or the environment” 
[109]. 
• NanoRiskCat, a risk categorization framework developed in Denmark, is “able to identify, 
categorize and rank exposures and effects of nanomaterials used in consumer products based 
on data available in the peer-reviewed scientific literature and other regulatory relevant sources 
of information and data” [110]. 
• The publications database available at nanoHUB [102] is useful for access to nanomaterial-
related information. 
• Standard methods and protocols are provided by various Federal agencies for guidance. For 
example, DOD utilizes a “watch list” of EHS-risk materials [111, 112]. 
• The method used by a 2012 EPA-funded study to prioritize risk based on stakeholder input is 
one example of prioritizing risk management needs. This study examined prioritizing research 
areas related to potential use of multiwalled CNTs in upholstery fabric [113]. 
• An “incremental approach” could be practical from both business and research perspectives. In 
such an approach, issues are prioritized by determining questions of immediate need. 
Chronological benchmarks are set for resolving these questions, and at each benchmark, 
progress and the costs and benefits of continuing the project can be evaluated. 
C. How are risk information and uncertainty factored into the decision? Some participants noted that 
risk and uncertainty affect decision making when actors weigh the amount of work and funding 
needed to conform to information reporting requirements. Risk and uncertainty also could influence 
decisions when actors take into account how the developing regulatory framework could restrict 
future activities. 
D. How can the NNI best support risk-based decisions? The discussion focused on increasing the 
accessibility and availability of relevant data. Organizing the available information and data 
(including “negative” or difficult-to-publish data showing no effect) into a central repository could 
greatly assist stakeholders. Some participants also identified confidential business information as a 
potential source of valuable information for risk management in this context and suggested that the 
NNI could investigate ways to identify common issues and trends reflected in this information, while 
still maintaining its confidential nature. Others expressed the view that basic research should 
continue to be funded so that fundamental data for risk assessment can be generated. 
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7. Breakouts Focused by 
Decision-Maker Community 
Stakeholders have perceptions of benefit and risk that affect their views of problems, processes, and 
solutions. These breakout sessions used the same vignette about Nanoparticle X and the same charge 
questions to identify the needs, perceptions, and approaches of seven different stakeholder 
communities when making decisions about nanotechnology risk. Again, each session began with 
presentations from the co-chair(s) on a real-world case study, followed by a group discussion regarding 
the charge questions. The discussions are summarized below. 
The Research Community 
Co-Chairs:  Christie Sayes, PhD, RTI International Jacqueline Isaacs, PhD, Northeastern University 
Case Presentations 
The co-chairs discussed using a life cycle approach (Figure 7.1) to understand the potential risks of two 
nanotechnology applications: the potential hazards of aerosol release from TiO2-enabled coatings (e.g., 
paints) and the theoretical end-of-life fate of electronic devices (e.g., cell phones) containing carbon 
nanotubes. 
The comments from session participants during the case study presentations included (1) there is a need 
to create incentives for industry players to address the potential environmental risks posed by 
nanotechnology-enabled products, (2) the public’s perception of a company’s “goodwill” could also play 
a role in motivating industry behavior, and (3) insurance companies influence industry behavior due to 
liability and risk leading to higher insurance costs. 
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Figure 7.1. The product life cycle approach to understanding exposure risks. (Figure courtesy of C. Sayes and J. 
Isaacs.) 
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Vignette Discussion 
Some breakout participants commented that risk-based decisions are essentially risk–benefit-based 
decisions. In particular, researchers may choose which nanomaterials to use in a given application based 
on the accessibility of the material, the challenge of incorporating it into a product, and the potential 
risks. Quantitative data on exposure at all stages of the life cycle and an ability to prioritize potential 
outcomes are critical for the decision-making process. 
Some participants argued that the insurance industry has a significant influence over risk-based 
decisions and could be better informed by studies conducted by the research community. In this case, 
collaborations between the research community and the insurance community could better guide risk–
benefit-based decision making, inclusive of the following: 
• Safety data sheets (SDSs, formerly known as material safety data sheets, MSDSs). 
• National Institute for Occupational Safety and Health Guidance documents [114]. 
• National Academy of Engineering (NAE) and National Academy of Sciences (NAS) reports. 
• Organisation for Economic Co-operation and Development publications [115]. 
• National Institute of Standards and Technology (NIST) standard reference materials [116]. 
• The National Institutes of Health (NIH) Nanomaterial Registry [63]. 
• Other reports and peer-reviewed literature. 
Session participants mentioned that limitations still exist for the tools listed above: inaccurate SDSs, 
cost-prohibitive reference materials, and insufficient characterization leading to irreproducible results. 
Comments from session participants on risk, uncertainty, and its communication on decision making 
included the following: 
• There is a lack of information regarding when and how exposure occurs throughout the life cycle 
with regard to workers, consumers, and the environment. Risk–benefit-based information is 
missing. 
• There is a need for data from case studies on realistic exposure scenarios, including hazard 
identification, in order to develop quantitative structure–activity relationships (QSARs). 
• Researchers should engage all stakeholders early in the process, so that research activities can 
be tailored to making informed decisions. 
Some participants recommended a number of steps that the NNI could take to assist the research 
community by making information available and accessible: 
• Supporting a repository for peer-reviewed SDSs. 
• Expanding the existing databases of information about ENMs (such as the Nanomaterial Registry 
[63]). 
• Developing a directory of decision makers (including insurance companies, government 
agencies, and other stakeholders) to improve communication and enhance collaboration.8 
                                                          
8 Contact information for Federal decision makers (www.nano.gov/partners), regional, State, and local resources 
(www.nano.gov/initiatives/commercial/state-local), industry collaborators (www.nano.gov/initiatives/commercial/industry-
collaborations), and more can be found at www.nano.gov. 
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The Regulatory Community 
Co-Chairs:  Janet Carter, MPH, Occupational Safety and Health Administration Jim Alwood, MS, U.S. Environmental Protection Agency Rick Reibstein, JD, Massachusetts Office of Technical Assistance and Technology 
Case Presentations 
Summary of Co-Chair Case Presentation—Ms. Carter 
The Occupational Safety and Health Administration is developing a searchable database for identifying 
the potential hazards posed by nanomaterials. This database will provide information about ENMs in a 
format that is both searchable and sortable and that allows for a comparison of nanomaterials. In 
addition, the database will identify research gaps and inconsistencies in the literature. The project, 
which also involves assessing the quality of the data included in the database, has so far identified 
approximately 1800 studies that contain usable information for the database (Figure 7.2). 
Summary of Co-Chair Case Presentation—Mr. Alwood 
EPA regulates carbon nanotubes under the Toxic Substances Control Act [46]. The agency has received 
new chemical notices under TSCA for over 150 nanoscale materials and over 60 types of CNTs and fibers. 
EPA has encountered challenges when assessing CNTs and fibers, due to several issues: 
• No nomenclature system has been developed for variations in structure or chirality. 
• Petitioners often submit insufficient data regarding relevant CNT properties. 
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Figure 7.2. The number of studies addressing the toxicity of a nanomaterial to humans, organized by year of 
publication, as of September 2013. Approximately 1800 of these studies can be found in the searchable 
database being developed by OSHA. (Figure courtesy of J. Carter.) 
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• The test methods used for gathering the submitted data are unclear. 
• Test results with which EPA is familiar may be inappropriate for CNTs. 
• It is unknown how the chemical–structural and material characterization properties of better-
known materials correlate with those of CNTs. 
Where data are lacking, under TSCA, EPA uses a bounding scenario that assumes that all CNTs are 
released into the environment, are persistent, bioaccumulate, and are highly mobile. Due to the 
uncertainty of the relevance of both hazard and exposure data, EPA has considered the human health 
effects of CNTs to be a potential unreasonable risk. Generation of additional data would be required if a 
company wanted to manufacture CNTs without the current restrictions found in previously issued 
consent orders. 
OECD plays a role in developing nanomaterial guidance documents and test guidelines [115]; the 
Canada–U.S. Regulatory Cooperation Council process is aimed at aligning the regulatory environment for 
nanomaterials between Canada and the United States [117]; and EPA is identifying research needs and 
collaborating with other agencies to develop data relevant to assessing the risks of ENMs. 
Summary of Co-Chair Case Presentation—Mr. Reibstein 
Lack of clarity in the regulatory environment is a detriment to industry as well as a failure to address the 
risks posed by nanotechnology. Clear regulations developed with the active engagement of 
knowledgeable practitioners would have a positive economic impact by reducing business risks. An 
effort should be made to avoid inherent toxicity at the early design stage, to understand risks presented 
by nanotechnology throughout the product life cycle, and to use democratic processes of deliberation, 
disclosure, and consensus-seeking among stakeholders. The Massachusetts Office of Technical 
Assistance and Technology has prepared a guidance document that describes these and other 
considerations for the safe development of nanotechnology [118]. 
Vignette Discussion 
Participants first discussed decisions faced by the regulatory community when determining what type 
and quantity of information are required before regulatory action can be taken, or if it is appropriate to 
take action at all. For instance, some participants noted that it first must be determined whether a 
product actually contains nanomaterials. One comment was that, unfortunately, data on nanomaterial 
content across business sectors are inconsistent, often reflected by the incomplete transfer of material 
information across the supply chain (e.g., information transfer through incomplete or inaccurate SDSs). 
In discussing risk assessment, some participants mentioned that the OECD nanomaterial guidance 
documents and test guidelines [115] are useful. Others noted that the regulatory structure for pre-
market testing is more developed than that for the post-market review of nanotechnology-enabled 
products. 
Breakout participants made the following suggestions concerning how NNI agencies can assist the 
nanotechnology risk management process: 
• Collaboration between the business and the regulatory communities is needed to ensure 
transparency, avoid ambiguity, and lessen market uncertainty and impacts for industry. 
• The NNI could help to facilitate this collaboration for good stewardship of nanotechnology by 
providing a framework for reasonable and responsible development. 
• This framework could be specific for each nanotechnology sector or application. 
• Some participants voiced the need for: 
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o More government–business liaison programs and public–private partnerships (PPPs) to 
develop guidance materials. 
o A national advisory committee to facilitate negotiated rulemaking with Federal agencies. 
o Programs that support industry consultation and public engagement throughout the entire 
regulatory process. 
o A program to help start-ups in their evaluation of risk. 
o Free assistance and resources for industry and business. 
The Nanomanufacturing Community 
Co-Chairs:  Craig Bandes, Pixelligent Technologies Ahmed Busnaina, PhD, Northeastern University 
Case Presentations 
Summary of Co-Chair Case Presentation—Mr. Bandes 
Pixelligent is a manufacturer of ZrO2 nanocrystal dispersions for electronics, semiconductors, and 
industrial markets. Industry leaders must often decide how and where to invest with imperfect 
information. Such business decisions are standard for industry players; however, the nanotechnology 
market presents an additional challenge due to lack of clarity in the regulatory framework. Industry and 
regulatory agencies must work together to create clear regulatory requirements that are informed by 
the needs of all stakeholders. Entrepreneurs in this emerging market already face many challenges, such 
as finding investors and obtaining the necessary capital. An unclear regulatory framework adds to these 
challenges and could prevent the successful commercialization of emerging technologies. 
Summary of Co-Chair Case Presentation—Dr. Busnaina 
Northeastern University’s Center for High-Rate Nanomanufacturing is developing a variety of 
technologies and applications related to advanced nanomanufacturing, including nanoscale templating 
and offset printing. It collaborates with a number of industrial partners and with NIOSH on worker 
safety. In order to address exposure concerns related to its manufacturing processes, the Northeastern 
research team members worked on high-rate toxicity testing and exposure assessment using a variety of 
techniques. They developed an EHS consortium and helped implement exposure and control evaluations 
in several company and research laboratories. This work contributed to a NIOSH safe practices 
document for ENMs [119]. 
In addition to EHS risks, business and market risks are critical considerations for developers of emerging 
technologies. For example, is there an existing infrastructure that supports their innovation? 
Researchers may have to develop specific applications for market acceptance. When smaller R&D 
projects aim to have their technology implemented at a commercial scale, it is often a “full-time job” to 
obtain the number of patents necessary to gain investment interest from larger companies. 
Vignette Discussion 
Comments offered by session participants included the following: 
• As for all businesses, nanomanufacturing decisions are driven by a risk–benefit analysis; any 
scale up and increase in volume must correlate with increased profitability. 
• Investment risks, as well as market potential, shelf life, and future processability, are also 
important. 
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• New precautions may be required to ensure worker and customer safety, even when there is a 
lack of data addressing such concerns. 
• Regulatory testing guidelines, data and reporting requirements, and the potential failure of the 
regulatory framework to distinguish between nanomaterials of dissimilar inherent hazards, all 
present business risks. When regulatory guidelines are unclear, nanomanufacturers must decide 
whether to spend resources on legal advice. 
• Agency–industry collaborations can be helpful, for example, the NIOSH guidance documents and 
field visits [114]. 
• Collaborations have not always facilitated a clear understanding by industry of applicable 
regulatory guidelines and how to meet them. To address this, the NNI could facilitate meetings 
between industry and regulatory agencies or agency visits to industry sites in order to support 
discussion of regulatory issues. 
• Transparency is important; the reasoning behind regulatory decisions could be made available 
to industry actors. 
The Small Business Community 
Co-Chairs:  Doyle Edwards, Brewer Science, Inc.  Richard Pleus, PhD, Intertox, Inc. 
Vignette Discussion 
The group focused the majority of its discussion on the Nanoparticle X vignette. Participants offered a 
variety of comments, including the following: 
• Small businesses would like a clear regulatory path or roadmap. Currently, the regulatory 
hurdles and associated costs and tasks for nanotechnology business development are not clear 
to start-up companies, compared to the known process of introducing new drugs and medical 
devices to commerce. A clearer path will allow investors to plan. 
• Risk-based decision making is a positive approach to understanding possible company-wide EHS 
risks. Additionally, could a small business somehow use data from an ENM already on the 
market? Examples include cost sharing or fees for use of data. 
• EHS data sets for analogous ENMs can help businesses predict worker exposure during 
manufacturing or potential environmental impacts. 
• A central repository of ENM test results and application data could facilitate innovation. 
• Businesses may consider foreign manufacturing locations that offer relaxed regulatory 
requirements but less focus on safety, thereby putting workers at greater risk. 
• Harmonizing domestic and international regulatory and safety guidance may facilitate global 
export and import markets. 
Participant comments on the tools that are available for risk management included the following: 
• NIOSH processes for evaluating occupational hazards are a helpful platform for industry. 
• Exposure could be contained with classical “engineering” controls; employees could be 
educated and protected using SDSs and other occupational safety tools with, at most, slight 
modification. 
• For understanding the physico-chemical properties of ENMs as they relate to assessing EHS risk, 
the Nanotechnology Characterization Lab, managed under the National Cancer Institute of the 
NIH [120], could also provide fundamental information on ENMs utilized in industry settings. 
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Some participants commented on limitations of available tools: 
• It is often difficult to ensure that engineering and education tools for ENM risk management are 
being used adequately, all the way down to the “worker level.” 
• Engineering controls are subject to some uncertainty because these tools are not always tested 
for effectiveness. 
• Efforts undertaken at the Nanotechnology Characterization Laboratory are limited to biomedical 
projects (i.e., to meet requirements for FDA review). 
• Small businesses often lack the support needed to translate risk-based information and to 
provide the appropriate level of guidance to workers (i.e., the type of support that would be 
given by an industrial hygienist). 
The Financial Risk Community 
Co-Chairs:  Clayton Shoup, M.A., C.I.H., C.S.P., Zurich North America Martha Marrapese, JD, Keller and Heckman LLP 
Case Presentations 
The co-chairs indicated that insurance companies recognize the importance of nanotechnology in the 
marketplace; these companies can facilitate effective risk management for industry by extending 
financial capital and risk management resources. However, availability of consistent, transparent, and 
reliable toxicity research data and standards affects the ability of an insurer to effectively provide this 
service. 
Summary of Co-Chair Case Presentation—Mr. Shoup 
The hypothetical case study presented involved a company that manufactures socks with a nanosilver 
coating. In order to assess the fees for insuring such a company, Zurich North America would use a 
proprietary nanotechnology risk assessment tool called the Zurich Nanotechnology Exposure Protocol 
(ZNEP™) [121]. The ZNEP™ protocol, developed in 2008, assesses coverage costs based on a variety of 
factors, including nanomaterial characteristics; the manufacturing processes used to develop the 
product or material; the control measures being used; the final form or use of the developed product; 
and scientific and regulatory information such as risk and toxicity studies, information on EHS best 
practices, and EHS regulatory data (see Figure 7.3). The ZNEP algorithm is used to develop underwriting 
intelligence to produce an individual risk rating. The gathered information is also used to provide risk 
management support to the company. This support could include assisting in the development of best 
practices and helping to facilitate risk communication. 
Vignette Discussion 
Some representatives from the insurance industry discussed how they first must determine whether the 
business causes some form of exposure to nanotechnology; if so, they then determine if and how to 
cover the business (fully insure, offer supplemental coverage, etc.) and the cost for that coverage. 
Underwriting processes are the primary tools used by the financial risk community for assessing risk. 
Collective “think tank”-style analyses and processes are among the methods utilized for underwriting to 
ensure consistency in decision making. Underwriting intelligence protocols and models can yield 
individual risk ratings, insurance product specifics, and ideas for risk management and mitigation 
support by evaluating the following factors: 
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• Material characteristics. 
• Toxicology data. 
• Existing regulations. 
• The manufacturing process used. 
• The final form and use of the product. 
• The control methods used by the company. 
Additional comments offered by breakout session participants included the following: 
• The primary limitation for underwriting in the nanotechnology sector is the lack of 
comprehensive risk-based data. Nondisclosures from businesses can limit access to key 
information, and regulatory uncertainty can limit the accuracy of the underwriting process. 
Additionally, data are only validated after they have been compiled over many years. 
• A “big-picture life cycle perspective” should be adopted when gathering data for risk assessment 
because insurance companies often provide coverage for a product throughout its life cycle. This 
approach is most effective when insurance companies have access to EHS data, information on 
best practices and good product design, and clear regulations, lessening uncertainty and thereby 
improving premiums and facilitating renewals. 
• Insurance companies also often gain information by consulting the Insurance Services Office 
[122] (which can gather data and recommend premiums) and through claims investigations. 
Therefore, existence of regulations, standards, or best practices throughout the life cycle of a 
product can help to resolve uncertainty and lead to more accurate decisions. 
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Figure 7.3. The Zurich Nanotechnology Exposure Protocol (ZNEP™), the nanotechnology risk assessment tool 
used by Zurich North America. Items in red text represent exemplar inputs for an evaluation of “Nano Sox.” 
(Figure courtesy of Zurich North America.) 
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Participants provided some suggestions on how the NNI could improve risk-based decision making, 
including the following: 
• Providing forums for discussion among stakeholders helps to inform the insurance community’s 
understanding of nanotechnology-related risks. In addition to the insurance industry, other 
financial stakeholders (such as investors) could be involved in this dialogue, allowing the 
different financial stakeholder groups to understand the drivers and needs of other 
communities. 
• More complete information on EHS risks is needed, including data addressing the long-term 
effects of nanotechnology applications. 
• Consistent and transparent methodologies and data reporting methods should be developed. 
• There is a need for clear and consistent standards and regulations, which will add certainty to 
the nanotechnology landscape. Regulatory alignment across agencies (i.e., OSHA, FDA, and EPA) 
and governments (e.g., the United States, Canada, and the European Union) is also important. 
Other Public Communities 
Co-Chairs:  David Berube, PhD, North Carolina State University Charles Geraci, PhD, National Institute for Occupational Safety and Health 
Case Presentations 
Summary of Co-Chair Case Presentation—Dr. Berube 
“Magic Nano” was an aerosol sealant used in bathrooms that was marketed in Germany. In 2006, 
reports that users of the product had experienced respiratory problems emerged, and six Germans were 
hospitalized after using the product. However, an investigation revealed that “Magic Nano” did not 
actually contain engineered nanoparticles. “Magic Nano” is but one example of a product that has used 
the “nano” prefix to suggest greater product value, even though the product does not actually contain 
ENMs [123]. 
Summary of Co-Chair Case Presentation—Dr. Geraci 
In one case, workers in China experienced adverse and, in certain cases, fatal health effects in an 
environment containing airborne nanomaterials [124]. However, without exposure data and because of 
other potential causes for the workers’ illness, the link between airborne nanoparticles and the workers’ 
disease was inconclusive [125]. 
Vignette Discussion 
Participants offered a variety of comments, including the following: 
• The public plays a fundamental role in deciding what constitutes acceptable risk with regard to 
nanotechnology. 
• Information on the effects of both acute and chronic nanomaterial exposure is needed to 
achieve an understanding of these potential hazards. 
• Advice on prudent protective measures, tailored to different public groups encountering 
exposure in different contexts, is critical. 
• The public also needs information regarding the quality of information conveyed in 
advertisements from marketers. 
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• A mechanism for the dissemination of comprehensible risk-based information to the public 
should be developed. 
• An understanding of the public’s threshold for information could also help to avoid information 
overload and an unnecessary expenditure of resources. 
• If members of the public do not trust the source of information, they will not incorporate that 
information into their decision making. Given the importance of trust, responsible governance is 
critical. The behavior of private companies can also greatly affect public trust. 
• Attitudinal and behavioral data that address how members of the public engage in reasoned 
action or planned behavior can help decision makers to anticipate public responses. 
• Information regarding the distribution of risks across groups or classes should be obtained 
because this information is necessary to assess the equity with which risks and benefits are 
being distributed or imposed. 
• Social science research can also be used to shed light on the public’s attitudes and perceptions 
of nanotechnology-related risks. 
• Given the public’s desire to be informed, uncertainty should be communicated to the public 
whenever possible. The level of complexity and specificity of this communication should be 
determined by the audience’s ability to comprehend this information. 
Participants discussed the various existing sources of information on nanotechnology-related risks, 
including media, Federal Government agencies (such as NIOSH, EPA, FDA, and CPSC), NGOs, and other 
stakeholder groups. Some participants identified media inaccuracies, the varying levels of trust held by 
government agencies, and the style of communication used by knowledgeable experts (which is not 
always ideal for communicating with the public) as limitations of these available sources. Others 
commented that the public lacks a “one-stop shop, go-to” place for information on the risks of 
nanotechnology; therefore, members of the public may struggle to find the appropriate sources of 
information. 
Suggestions offered by participants for the NNI to assist public risk-based decision making included the 
following: 
• Support a national center that targets different stakeholder audiences and educates these 
audiences so that they may engage in informed risk-based decision making. 
• Provide ongoing, adequate support for risk communication between multiple audiences and 
stakeholder groups. 
• Support a research center that joins government agencies and other stakeholder groups in 
collaborative risk assessment projects. 
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The NGO Community 
Co-Chairs: Terry Gordon, PhD, New York University School of Medicine and the American Conference of Governmental Industrial Hygienists Carolyn Cairns, MPH, Independent consultant in Environmental Health, Sustainability, and Product Safety Science 
Case Presentation 
Summary of Co-Chair Case Presentation—Dr. Gordon 
Various NGOs have made efforts to develop environmental exposure threshold limit values (TLVs) and 
occupational exposure limits for nanoparticles. Examples of NGOs that work to set OELs include the 
American Conference of Governmental Industrial Hygienists (ACGIH) TLV Committee [126], Germany’s 
Permanent Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the 
Work Area [127], the Occupational Alliance for Risk Science (OARS) managed by the Toxicology 
Excellence for Risk Assessment group [128], and the Scientific Committee on Occupational Exposure 
Limits of the European Commission [129]. 
The process of setting OELs requires a significant amount of peer-reviewed data, such as human or 
animal studies, data to determine no-observed-adverse-effect levels (NOAELs), and reliable size data to 
compare materials. Other than ZnO and TiO2, there are too few “nano” substances with sufficient data 
sets to set OELs. Therefore, the ACGIH TLV committee has begun to experiment with using benchmark 
materials for setting OELs when data are limited. However, extrapolating from a benchmark dose 
introduces significant uncertainty, and there is currently no reliable substitute for in vivo testing. 
Vignette Discussion 
Breakout participants addressed the issues presented in the vignette by considering a hypothetical 
example of nanoparticles in paints, coatings, and potentially, food packaging. Since some participants 
wanted a real-world example, the discussion ended up focusing on the use of nanoparticles in 
commercial sunscreens. The following risk-based information was suggested by some NGO-affiliated 
participants as necessary for making decisions in this context: 
• Information on which sunscreens contain nanomaterials. 
• Data on what makes the “nano ingredients” in commercial sunscreens toxicologically or 
functionally different from conventional ingredients. 
• Analytical methods and standard nomenclatures to characterize and identify nanomaterials in 
sunscreens. 
• Data on the performance of nanotechnology-enabled sunscreens (i.e., how do sunscreens 
containing nanoparticles compare with conventional sunscreens with respect to sun damage 
protection?). 
Participants suggested some potential information needs: 
• Verified information on which commercial products contain ENMs. 
• Data on the environmental fate of ENMs, their impact on biological systems, and their 
transformational effects under environmental conditions. 
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• Published studies investigating the safety of actual commercial products, as opposed to discrete 
ingredients or simulated products. 
• Data on the environmental and health effects of ENM aggregation or agglomeration. 
Some breakout session participants suggested that premarket safety testing of final products (as 
opposed to just ingredients) or implementation of a meaningful practice of public disclosure for ENM 
use in consumer products could help to address these substantial data gaps. Suggestions for moving 
nanotechnology risk management practice forward included the following: 
• The existing EHS data on ENMs should be organized and made easily accessible. 
• A standard set of toxicity testing methods for ENMs could be developed and promoted. 
• Studies should be supported to determine the predictive value of in vitro testing methods for 
assessing in vivo health effects. 
• Studies should be supported that address the risks presented by ENMs in various exposure 
scenarios and in various stages of the product life cycle. 
• Studies should be supported that address the presence or absence of ENMs in consumer 
products, the development of methods to characterize potential exposure that could result from 
the ENMs as presented in these products, and the effects of such exposure. 
• A future workshop could gather multiple stakeholder groups to determine how to achieve 
meaningful disclosure of ENM use in consumer products and in occupational settings. 
• An inventory could be developed that lists the presence of ENMs in consumer products and in 
occupational settings. 
• Involvement of the Agency for Toxic Substances and Disease Registry (ATSDR) could be 
supported in the communication and management of the risks presented by ENMs.
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8. Roundtables 
Parallel roundtable sessions were convened after the breakout sessions. These moderated sessions 
provided participants with an opportunity to voice questions or discuss issues that had not been the 
topic of the previous structured discussions. The roundtable discussions are summarized below. 
Roundtable 1: The Needs and Perspectives of Emerging Business 
Moderator: Jay West, American Chemistry Council 
Emerging businesses compartmentalize their risks (regulatory risks, market risks, etc.) and then 
determine whether a specific risk is acceptable. These decisions are based on a risk–benefit analysis; 
risks are inherent in many products, and all businesses accept some amount of risk, regardless of the 
business context. However, participants offered comments on several specific challenges for emerging 
businesses involved in nanotechnology: 
• There is no “roadmap” for an emerging business producing nanotechnology-enabled products, 
as there is for drug development [130] or emerging technologies in the semiconductor industry. 
• There is not enough communication between agencies and businesses regarding regulatory 
requirements and best practices. Small nanomanufacturing companies encounter difficulties 
when trying to do business with larger industries as a result of this lack of regulatory clarity, 
thereby impeding industry collaboration. 
• “User-friendly” information relating to the risks of nanotechnology is scarce. Often, the available 
data are not summarized and simplified, making the data difficult to use for businesses that lack 
specialized technical expertise. 
• Some companies may avoid participation in meetings such as this workshop, to minimize the 
perception that their “nano” activities represent risk; the NNI could address this by increasing its 
outreach to small businesses. 
Roundtable participants made several suggestions for assisting the emerging-business community, 
including the following: 
• Create a repository of “user-friendly” information on nanotechnology risk. For example, the 
“Good Nano Guide” [98] was cited as one helpful resource that is available. The repository could 
also include Federal agency contact details so that users can receive clarification, if necessary. 
• Provide concrete guidance for emerging businesses relating to realistic scenarios. Guidance for 
introducing new products could also be provided. In particular, “step-by-step” guidance for 
meeting the regulatory requirements of OSHA and EPA is needed. These roadmaps would be 
pivotal for reducing business uncertainty and would assist small businesses in their attempt to 
engage with larger industries. 
• Improve methods for outreach or communicating with the small business community. For 
example, the Small Business Innovation Research and Small Business Technology Transfer 
(SBIR/STTR) programs [131] were suggested as vehicles to engage with small businesses. These 
programs could provide information that would direct businesses to EHS resources. Agencies 
participating in the NNI could also share their best practices for engaging small businesses. 
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• Make liaisons available to small businesses with regulatory agencies and agencies 
participating in the NNI through a defined procedure. EHS subject-matter experts in Federal 
agencies could act as liaisons with the small business community. For example, NIOSH engages 
in productive communication with businesses, and NIOSH field teams help to address some of 
the practical and financial barriers that the businesses face [99]. CPSC also has a small 
collaborative segment that helps industry actors to develop methods for testing product safety 
[132], although this service may not be applicable to nanotechnology companies creating 
products that are not final consumer products. Creation of liaison teams from regulatory 
agencies such as EPA would be beneficial to the small business community. 
Roundtable 2: A Sector-Based Approach: Perspectives from the Pharmaceutical 
Industry 
Moderators:  Frank Malinoski, PhD, Liquidia Technologies, Inc.  Lawrence Tamarkin, PhD, CytImmune Sciences, Inc. 
The roundtable began with presentations by the moderators on Liquidia’s particle replication in non-
wetting templates (PRINT) technology for vaccine manufacturing, and on CytImmune’s nanotechnology-
enabled drug delivery system, AurimuneTM [133]. 
In the ensuing discussion, moderators and roundtable participants offered a variety of comments, 
including the following: 
• Specific technical challenges need to be addressed when characterizing complex nanomedicines 
and when manufacturing these drugs at the commercial scale. 
• Given the large investment that is required to bring a drug to market, investing in 
nanotechnology-enabled drug development may be perceived as a significant business risk, but 
this risk is no greater than traditional new drug entities. 
• The U.S. regulatory framework is sufficiently comprehensive to accommodate and support the 
development of nanomedicines and allows for specific considerations on a case-by-case basis. In 
particular, the Food and Drug Administration guidelines on Pharmaceutical Development [130], 
Quality Risk Management [134], Pharmaceutical Quality System [135], and the principles of 
Quality by Design (QbD) [130] all provide a valuable framework for nanomedicine development. 
• The efforts of the National Cancer Institute (NCI) at the Nanotechnology Characterization 
Laboratory (NCL) [136] have also helped move nanomedicine development forward. By 
characterizing nanomedicines submitted by industry, this resource provides valuable third-party 
validation and characterization of nanomaterials being developed for use in medical products. 
Such assurance is vital for small businesses. 
• The NCI Translation of Nanotechnology in Cancer (TONIC) group has assisted in the development 
of nanomedicines for cancer treatment by encouraging collaborative industry and government 
agency efforts [137]. 
Various suggestions were offered regarding how NNI support can help to move the field of 
nanomedicine forward: 
• Continue to support independent third-party validations of data, such as the efforts taking 
place at NCL. 
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• Continue to support collaborative endeavors between industry and government agencies, 
such as those of the TONIC group. Industry–agency alliances may be helpful in other 
nanotechnology sectors as well. 
• Support the education of pharmaceutical companies and the public on the benefits of 
nanomedicines. Ultimately, pharmaceutical companies determine which drugs will be 
developed through their investment decisions. Educating the public on the benefits of 
nanomedicines will help to ensure a market for these drugs, thereby encouraging industry 
investment. 
• Continue to support FDA’s regulatory efforts to ensure that these efforts keep pace with the 
scientific and technical developments occurring in the pharmaceutical industry. 
Roundtable 3: Public Risk Perception and Communication 
Moderators:  Barbara Herr Harthorn, PhD, University of California, Santa Barbara David Andrews, PhD, Environmental Working Group 
This roundtable began with case study presentations by the moderators. Dr. Andrews discussed the 
seventh annual review of sunscreens by the Environmental Working Group (EWG) [138], which 
evaluated the modeled efficacy and the health hazards associated with the listed ingredients of nearly 
1400 products. The evaluation of health hazards was based on a review of nearly 60 industry, academic, 
and government regulatory and toxicity publications and databases, as well as the peer-reviewed 
literature. When conducting the toxicity review of nanomaterials in sunscreens, a primary focus was 
exposure via dermal absorption. The literature review revealed minimal evidence of dermal penetration 
by ENMs at any size scale, and the reviewers ultimately recommended sunscreens containing ZnO and 
TiO2 nanoparticles as viable options for consumers seeking sun protection. Products with ZnO and TiO2 
ranked high on the list of recommended products because of their efficacy in providing ultraviolet A 
(UVA) as well as ultraviolet B (UVB) protection with minimal concerns in regard to toxicity. The report 
also recommended that powders and lip products containing TiO2 nanoparticles be avoided; this 
precautionary recommendation was based on the proximity to the mouth and based largely on a lack of 
information. There were also concerns regarding mineral structure, particularly with respect to TiO2, 
because the anatase crystal phase of this material has been shown to be more reactive than other 
forms. 
Dr. Harthorn discussed effective methods to engage the public and to ensure that decisions based on 
empirical evidence about the societal as well as technical aspects are made with respect to 
nanotechnology. She noted that information such as the sunscreen data should be presented in a way 
that is easily understandable by members of the general public since they may not readily identify 
technical inaccuracies, misleading information, or gaps in the data. 
The roundtable moderators and other participants offered suggestions for improving public risk 
perception and communication, including the following: 
• Nanomaterials should be treated as if they are new chemicals, and research should be done in 
order to determine which nanomaterials pose EHS risks and which do not. 
• An authoritative, trusted, “go-to” source of information is needed. For instance, a website 
could be created that contains centralized, synthesized information about nanotechnology for 
consumers. GreenFacts [139] was identified as an example of a resource that successfully 
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communicates EHS information to a lay audience. Safety data sheets are needed that 
adequately differentiate nanoscale materials. 
• Best practices should be developed for engaging with diverse audiences and communicating 
information about nanotechnology. For instance, forms of certification and labeling of 
nanotechnology-enabled products should be encouraged. However, labeling may present other 
issues: labeling could cause distrust simply due to the existence of the label, and labels may not 
be an effective means to communicate information. In particular, labeling a product as “nano” 
may not address the public’s primary concern, which is simply to know whether these 
nanotechnology-enabled products are safe. 
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9. Recurring Themes 
The NNI R3 Workshop was organized to assess the state of practice and tools for risk assessment and 
management, how sector-specific perspectives may influence these practices, and ways that NNI 
agencies can assist stakeholders in the responsible development of nanotechnology. This workshop was 
designed to gather data from a wide range of stakeholders in a “top-down” fashion by focusing on 
identifying types of decisions and decision-maker needs that guide nanotechnology risk assessment and 
risk management. 
State of Practice and Available Tools 
Few nanomaterials have been well characterized, and even those evaluated may not have been 
assessed for each part of the life cycle, especially as they are actually functionalized in the final 
technology or product. Therefore, much of the state of practice in risk management for nanotechnology 
presented at the workshop involved dealing with uncertainty due to the limited amount of data. More 
than one presenter stressed, however, that even with quantitative data, valuations of risk cannot be 
defined objectively without considering stakeholder values. This necessitates a dialogue between risk 
managers and other stakeholders early and often in the risk management process. The ability to act 
more swiftly using incomplete or qualitative data in a protective manner was encouraged. Since both 
qualitative- and quantitative-based risk management practices involve subjective valuations of risk (e.g., 
the relative value of reduced longevity of people in different age classes), assumptions and valuations 
should be made transparent and explicit. Decision analysis was mentioned as a way to standardize and 
make more explicit this decision-making process. 
Stakeholders presented several tools in use to assess risk in the face of incomplete data, including life 
cycle analysis (LCA), screening-level risk assessment tools (e.g., control banding), alternative analysis 
tools (e.g., multicriteria decision analysis), and decision analysis tools (e.g., value of information 
analysis). Life cycle analysis for evidence-based nanotechnology risk assessment was a practice common 
across stakeholder groups. This type of analysis can be populated with characterization and EHS data 
from databases like the Nanomaterial Registry [63] and can help focus future data collection efforts. 
Grouping materials with similar function, physico-chemical similarity, or exposure outcomes was 
presented as a way to deal with missing data using a method called “control banding.” This method 
incorporates Lawrence Livermore probability and risk severity scores [55]. Comparative risk assessment 
(also called an “alternatives analysis”), instead of the classical risk model of identify, quantify, and 
control, is where functional, non-nanoscale alternatives are compared with the subject of assessment. 
GreenScreen [87] was offered as a tool to facilitate alternatives analysis by providing a screening 
measure that uses existing data along with substitute values for missing data. These substitute data 
have been evaluated through systematic review by certified profilers to verify that the substitution can 
be performed scientifically. Value-of-information analysis was cited as a tool to “quantify…the potential 
benefit of additional information in the face of uncertainty” [105]. Structured decision making was 
discussed as a way to deal with qualitative data and to standardize the risk management process. 
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The need for more widely used standards for testing methods, exposure thresholds, and procedural 
guidelines was mentioned repeatedly. Several resources in this area were identified by participants: 
• International documents (ASTM [57] and ISO [58]). 
• U.S. Government documents: 
o NIST standard reference materials [116]. 
o FDA guidelines on: 
 Pharmaceutical Development [130]. 
 Quality Risk Management [134]. 
 Pharmaceutical Quality System [135]. 
 The principles of Quality by Design [130]. 
o OSHA OELs and SDSs. 
o NIOSH guidance documents [114]. 
Additionally, members of the financial risk community (i.e., insurance industry) stated that they gain 
information by consulting the Insurance Services Office [122] (which can gather data and recommend 
premiums) and through claims investigations. The ACGIH Threshold Limit Values (TLV) Committee [126] 
is also known to set occupational exposure limits. 
A complete list of tools and standards mentioned can be found in Appendix D. Additionally, Table 9.1 
synthesizes the topics that were discussed by the participants in the general and breakout sessions that 
took place during the course of the R3 Workshop. 
Stakeholder Perspectives on Risk 
The public plays a fundamental role in deciding what constitutes acceptable risk with regard to 
nanotechnology. As highlighted by the keynote speakers, stakeholder perceptions are complex and 
require expert analysis to understand potentially subtle or obscure ethical complexities; empirical 
evidence indicates that using an intuitive understanding of “risk” to respond to societal needs is faulty. 
Stakeholder values should be integrated early on into the risk management process since effective risk 
communication and management will help to align actual risk and perceived risk. 
Although the stakeholder perspectives varied somewhat, most groups represented at the workshop 
expressed the desire for more information on the potential hazards of and exposure to nanotechnology. 
Research shows that technical risk data alone will not affect decisions consistently; judgments by 
different stakeholders with varying biases, values, and stances can affect how consumers, regulators, 
developers, and insurers behave [33]. Even when available, decision makers may not be clear what 
weight or value is appropriate to place on certain data when setting policy. Formal decision analytical 
tools can help in placing these weights and values in a transparent way. For the business community, 
data gaps and public perceptions of risk are both important in terms of responsible development, 
regulatory compliance, and market acceptance. Overall, better outcomes will result if these issues are 
explicitly addressed. 
Suggestions to NNI Agencies 
Workshop participants were asked to suggest ways in which NNI agencies can best support risk-based 
decision making. Notable suggestions can be grouped broadly into three categories: communication 
resources, decision tools and data resources, and standardization and guidance resources. 
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Facilitate Communication 
Several suggestions to the NNI agencies centered on facilitating opportunities for better communication 
between the government and the private sector, and providing fora for continued communication 
among stakeholders. 
Table 9.1. Synthesis of topics discussed by breakout session and group 
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Methods/Tools for Detection 
and/or Characterization of 
ENMs 
          
Toxicology Studies on ENMs           
Repository of Information           
Models for Exposure           
Transparent Reporting of 
ENM Presence Across the 
Supply Chain 
          
Communication and Decision 
Tools           
Data Quality           
A Clear Roadmap or 
Framework for Regulatory 
Compliance 
          
Addressing EHS Issues at an 
Early Stage 
          
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Standards and Guidances for 
Risk Assessment and 
Management 
          
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Improve Government–Business Communication 
It was suggested that the NNI support more government–business liaison programs. Nanotechnology 
developers expressed a desire for assistance from the NNI in interfacing with government organizations, 
especially when dealing with sensitive confidential business information or intellectual property. Such 
data would also be useful to academic researchers studying hazards and exposure. It was suggested that 
NNI agencies could investigate ways to identify common issues and trends reflected in this information, 
while still maintaining its confidential nature. It was also suggested that the Federal NNI agencies work 
with State governments to help develop integrated and consistent approaches for risk management. 
Finally, a directory of agency decision makers and points of contact was desired.9 
Continue Support for Stakeholder Workshops 
Additional stakeholder workshops to facilitate responsible development of nanotechnology were 
suggested, along with meetings with Federal and non-Federal stakeholder groups (such as 
manufacturers and small businesses) to discuss nanotechnology-related risk management. Specific 
workshops suggested included the following: 
• Multiple stakeholder groups to determine how to achieve meaningful disclosure of ENM use in 
consumer products and in occupational settings. 
• The research and insurance communities to help inform risk-based decisions in underwriting. 
• Industry and government to develop a regulatory framework. 
Provide Decision Tools and Data Resources 
The most often heard suggestions for the NNI agencies were to provide an authoritative point source of 
information, tools, and resources, and to continue to support risk communication between stakeholder 
groups. 
Create an Independent Risk Management Center and/or a Central Repository for Exposure and Hazard 
Information Related to Nanotechnology 
More than one participant suggested that the NNI agencies could support an independent risk 
management resource center. Such a center would be a repository for support and information, could 
anticipate problems and pool lessons learned, and could facilitate independent third-party validations of 
data such as the efforts taking place at the NCL. 
As a variation on that theme, it was suggested that the NNI host a central repository for exposure and 
hazard information related to nanotechnology. The need for a trusted, central repository of information 
related to potential risks of nanotechnology was expressed. This “one-stop-shop” could host links to 
databases and other resources such as the following: 
• Existing nanoEHS information on nanotechnology-enabled products. 
• OSHA SDSs. 
• Difficult-to-publish but useful data (“negative results”). 
• Standards relevant to nanomaterials. 
• Test methods. 
                                                          
9 Contact information for Federal decision makers (www.nano.gov/partners), regional, State, and local resources 
(www.nano.gov/initiatives/commercial/state-local), industry collaborators (www.nano.gov/initiatives/commercial/industry-
collaborations), and more can be found at www.nano.gov. 
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• Occupational exposure limits. 
• Material physico-chemical characteristics and EHS data (Nanomaterials Registry). 
• Guidance documents from FDA, OECD, NIOSH, and ACGIH. 
• Risk management tools. 
Provide Standards and Guidances 
The need for examples of best practices in the form of standards and guidance resources was 
mentioned throughout the workshop (see list above). Specifically, such documents can help small 
businesses in the responsible development of nanotechnology. 
Provide Guidance for Small Businesses 
Representatives of the small business community stated that they could use assistance from the NNI 
agencies in interpreting and navigating the regulatory process with regard to nanomaterials. Some 
suggestions were to offer free assistance and resources (though a fee could be charged similar to the 
Prescription Drug User Fee Act [14]), make use of SBIR/STTR programs [131], develop a program to help 
start-ups in their evaluation of risk (i.e., the type of support that would be given by an industrial 
hygienist), develop a “roadmap” or “framework” to facilitate the development of nanotechnology-
enabled applications through the regulatory process, and support more public–private partnerships and 
collaborative endeavors between industry and government. 
The Path Forward 
The R3 workshop successfully brought together a wide range of stakeholders who presented a variety of 
methods and tools that can be used to evaluate the potential risks of nanomaterials across the life cycle. 
Risk assessors, including professionals from small companies, environmental groups, occupational 
health and safety organizations, and insurance companies, outlined the criteria and approaches that 
they currently use for nanomaterial evaluations. Although still in the nascent stages of nanotechnology 
risk assessment and management, the participants demonstrated that a combination of existing tools 
and data can be used to support science-based decisions regarding implications from the use of 
nanomaterials in a range of scenarios. Integration of risk assessment and management requires 
supplementing traditional quantitative risk assessment tools with emerging methods such as life cycle 
and decision analysis. To support the sustainable development of nanotechnology, the risk community 
must continue this dialogue. Such collaborative efforts will help improve existing methods and develop 
new communication approaches that provide a better understanding of potential environmental and 
health implications of nanotechnology-enabled products. 
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Appendix A. Workshop Agenda10 
2013 NNI Workshop on Stakeholder Perspectives on Perception, Assessment,  
and Management of the Potential Risks of Nanotechnology 
Tuesday September 10, 2013 
8:30 – 8:35  Introductions 
 Igor Linkov (Department of Defense), Treye Thomas (Consumer Product Safety 
Commission), Jeff Steevens (Department of Defense) 
8:35 – 8:50  Welcome, NNI Overview, and Charge to Participants [PDF] 
 Altaf Carim (Office of Science and Technology Policy) 
8:50 – 9:00  Activities since the 2010 NNI Capstone Meeting and Expectations 
 Treye Thomas (Consumer Product Safety Commission) 
 
SESSION 1:  A Snapshot on the Perception, Assessment, and Management of the Potential Risks of 
Nanotechnology  
Moderator: Mark Wiesner (Duke University) 
9:00 – 9:20  A Perspective from Industry [PDF] 
 Stephen Gibbons (Brewer Science, Inc.) 
9:20 – 9:40  A Perspective from the Consumer Community [PDF] 
 Michael Hansen (Consumers Union) 
9:40 – 10:00  A Perspective from the Labor Community [PDF] 
 Darius Sivin (The International Union, United Automobile, Aerospace and Agricultural 
Implement Workers of America) 
10:20 – 10:40  A Perspective from the Standards Community [PDF] 
 Ajit Jillavenkatesa (National Institute of Standards and Technology) 
10:40 – 11:00  A Perspective on Regulations [PDF] 
 Timothy F. Malloy (University of California, Los Angeles) 
11:00 – 11:20  A Perspective from the NGO Community [PDF] 
 Jennifer Sass (Natural Resources Defense Council) 
11:20 – 11:50  Discussion with Panel of Morning Speakers 
 
11:50 – 12:00  Charge to Breakout Participants 
 Jeﬀ Steevens (Department of Defense) 
  
                                                          
10 NOTE: The original full agenda, including times for coffee and lunch breaks, as well as the copies of the presentation slides, may be 
found at the NNI workshop webpage, www.nano.gov/R3workshop. This version notes the substantive activities only. Additionally, a 
webcast of most presentations is available at www.tvworldwide.com/events/nnco/130910. 
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SESSION 2: BREAKOUT SESSIONS (PART 1) 
13:00 – 16:00 PARALLEL BREAKOUT SESSIONS BY TYPE OF DECISION 
Group 1: Occupational Risk Analysis and Decision Making 
Chairs: Paul A. Schulte (National Institute for Occupational Safety and Health) 
Bruce Lippy (CPWR—The Center for Construction Research and Training) 
Group 2: Commercial Product Life Cycle Stage 
Chairs: Rick Canady (International Life Science Institute) 
Todd Kuiken (Woodrow Wilson International Center for Scholars) 
Group 3: Environmental Life Cycle Implications 
Chairs: Tom Seager (Arizona State University) 
Matthew Hull (Virginia Tech) 
 
SESSION 3: REPORT BACK AND SYNTHESIS CONVERSATION 
 Moderators:  Treye Thomas (Consumer Product Safety Commission)  
  Christine Hendren (Duke University) 
16:30 – 17:00 Summary of Breakout Sessions 
 Breakout Session Co-Chairs 
17:00 – 17:15 Discussion and Public Comments 
 
Wednesday September 11, 2013 
8:30 – 8:45 Recap of Day 1 and Instructions for Day 2 [PDF] 
Igor Linkov (Department of Defense) 
SESSION 4: Keynote: Perspectives on Risk Analysis 
Moderator: Igor Linkov (Department of Defense) 
8:45 – 9:15 Broader Review and Perspectives on Risk Analysis [PDF] 
 Baruch Fischhoﬀ (Carnegie Mellon University) 
9:15 – 9:45 Nanotechnology Multi-Stakeholder Risk Perception: Implications for Risk Analysis, 
Management, and Communication [PDF] 
 Barbara Herr Harthorn (University of California, Santa Barbara) 
 
SESSION 5:  BREAKOUT SESSIONS (PART 2) 
10:15 – 12:15 Parallel Breakout Sessions by Type of Decision Maker 
Group 1: The Research Community 
Chairs:  Christie Sayes (Research Triangle Institute) 
Jackie Isaacs (Northeastern University) 
Group 2: The Regulatory Community 
Chairs:  Rick Reibstein (Massachusetts OTA)  
Janet Carter (Occupational Safety and Health Administration) 
Jim Alwood (Environmental Protection Agency) 
Group 3: The Nanomanufacturing Community 
Chairs:  Ahmed Busnaina (Northeastern University) 
Craig Bandes (Pixelligent Technologies) 
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Group 4: The Small Business Community 
Chairs:  Doyle Edwards (Brewer Science, Inc.) 
Rick Pleus (Intertox, Inc.) 
Group 5: The Financial Risk Community 
Chairs:  Martha Marrapese (Keller Heckman LLP)  
Clayton Shoup (Zurich North America) 
Group 6: Other Public Communities 
Chairs:  David Berube (North Carolina State University) 
Charles Geraci (National Institute for Occupational Safety and Health) 
Group 7: The NGO Community 
Chairs:  Terry Gordon (American Conference of Governmental Industrial Hygienists, NYU School of Medicine) 
Carolyn Cairns (Independent Consultant) 
 
SESSION 7:  REPORT BACK AND SYNTHESIS CONVERSATION 
 Moderators:  Jeff Steevens (Department of Defense)  
  Carolyn Cairns (Independent Consultant) 
12:15 – 13:00 Summary of Breakout Sessions 
 Breakout Session Co-Chairs 
 
SESSION 8: PARALLEL ROUNDTABLE SESSIONS & CONCLUDING REMARKS 
14:00 – 16:00 Roundtable Discussion Groups: 
 Group 1: Needs and Perspectives of Emerging Business 
 Moderator: Jay West (American Chemistry Council) 
 Group 2: A Sector-Based Approach: Perspectives from the Pharmaceutical Industry 
 Moderators: Frank Malinoski (Liquidia Technologies, Inc.)  
Lawrence Tamarkin (CytImmune Sciences, Inc.) 
 Group 3: Public Risk Perception and Communication 
 Moderators:  Barbara Herr Harthorn (University of California, Santa Barbara) 
David Andrews (Environmental Working Group) 
16:30 – 17:00 Summary and Discussion of Roundtable Sessions 
 Moderator: Jeff Steevens (Department of Defense) 
17:00 – 17:15 Discussion and Public Comments 
 
17:15 – 17:30 Concluding Remarks 
Igor Linkov, Risk and Decision Science Focus Area Lead, U.S. Army Engineer Research and 
Development Center, Department of Defense 
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Appendix B. Workshop Participants11 
Names A nd Affiliations 11 
Jim Alwood  
Environmental Protection 
Agency 
David Andrews  
Environmental Working Group 
Craig Bandes  
Pixelligent Technologies, LLC 
Maria Bastaki  
Verto Solutions, LLC 
Jewel Beamon  
National Nanotechnology 
Coordination Office 
David Berube  
North Carolina State University 
Public Communication of Science 
& Technology Project 
Elizabeth Beryt  
UC Center for Environmental 
Implications of Nanotechnology, 
Luskin Center for Innovation 
Adrienne Black  
Grocery Manufacturers 
Association 
William Boyes  
Environmental Protection 
Agency 
Elizabeth Boyle  
Westat 
Michael Boyles  
Department of Commerce 
Faye Bresler  
Department of Defense, Defense 
Logistics Agency 
Tim Brown  
Consumer Specialty Products 
Association 
George Burdock  
Burdock Group 
Mary Busby  
James River Insurance 
                                                      
11 NOTE: Participants’ affiliations are as 
of the date of the workshop. 
 
Ahmed Busnaina  
Northeastern University 
Carolyn Cairns  
Consultant 
Rick Canady  
International Life Sciences 
Institute 
Chris Cannizzaro  
Department of State 
Vincent Caprio  
NanoBCA 
Altaf Carim  
Office of Science and Technology 
Policy, Executive Office of the 
President 
Janet Carter  
Occupational Safety and Health 
Administration 
Russ Castioni  
3M 
Samar Chatterjee  
SAFE Foundation 
Fan-Li Chou  
Department of Agriculture 
Khershed Cooper  
National Science Foundation 
Jed Costanza  
Environmental Protection 
Agency 
Donna Cragle  
Oak Ridge Associated 
Universities 
Cheryl David-Fordyce  
National Nanotechnology 
Coordination Office 
Kerry Dearfield  
Department of Agriculture, 
Office of Public Health Science 
Vicky Doan-Nguyen  
University of Pennsylvania 
Patricia Downs  
Occupational Safety and Health 
Administration 
Jonathan Dumke  
Louisiana State University 
Maureen Dunn 
Doyle Edwards  
Brewer Science, Inc. 
Donald Ewert  
nanoTox, Inc. 
Tarek Fadel  
National Nanotechnology 
Coordination Office 
Baruch Fischhoff  
Carnegie Mellon University 
Lisa Friedersdorf  
National Nanotechnology 
Coordination Office 
Steffi Friedrichs  
Nanotechnology Industries 
Association 
Martin Fritts  
Frederick National Laboratory 
for Cancer Research 
Dannielle Fugere  
As You Sow 
Alan George  
ILC Dover 
Charles Geraci  
National Institute for 
Occupational Safety and Health 
Steve Gibbons  
Brewer Science, Inc. 
Hilary Godwin  
University of California, Los 
Angeles, School of Public Health 
Wayne Gokey  
Navy Bureau of Medicine and 
Surgery 
Terry Gordon  
NYU Langone Medical Center 
American Conference of 
Governmental Industrial 
Hygienists 
Khara Grieger  
RTI International 
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Pertti Hakkinen  
National Institutes of Health, 
National Library of Medicine 
Shannon Hanna  
National Institute of Standards 
and Technology 
Michael Hansen  
Consumers Union 
Jaydee Hanson  
International Center for 
Technology 
Michael Heintz  
Association of Public Health 
Laboratories 
Christine Hendren  
Duke University Center for the 
Environmental Implications of 
NanoTechnology 
Barbara Herr Harthorn  
University of California, Santa 
Barbara 
Geoffrey Holdridge  
National Nanotechnology 
Coordination Office 
Matthew Hull  
Virginia Tech  
NanoSafe Inc. 
Robert Iafolla  
Bloomberg Bureau of National 
Affairs, Inc. 
Jackie Isaacs  
Northeastern University 
Ajit Jillavenkatesa  
National Institute of Standards 
and Technology 
Christopher Jones  
Office of Science and Technology 
Policy, Executive Office of the 
President 
Danielle Jones  
Office of Management and 
Budget, Executive Office of the 
President 
Erica Jones  
Exxon Mobil 
Dorothy Jones-Davis  
National Science Foundation 
Debra Kaiser  
National Institute of Standards 
and Technology 
Barbara Karn  
National Science Foundation 
Akbar Khan  
Department of Defense, Defense 
Threat Reduction Agency 
Marilyn Khanna  
Food and Drug Administration 
Michael Kiley  
National Nanotechnology 
Coordination Office 
James Kim  
Office of Management and 
Budget, Executive Office of the 
President 
Fred Klaessig  
Pennsylvania Bio Nano Systems, 
LLC 
Eva Knoth  
Eastern Research Group 
Sharon Ku  
Drexel University 
National Institutes of Health 
Todd Kuiken  
Woodrow Wilson Center 
Girish Kumar  
Food and Drug Administration 
Elyse Lee 
Igor Linkov  
Army Corps of Engineers 
Bruce Lippy  
CPWR—The Center for 
Construction Research and 
Training 
Maggie Liu  
NanoMedicine Alliance 
Gediminas Mainelis  
Rutgers University 
Frank Malinoski  
Liquidia Technologies
Timothy Malloy  
University of California, Los 
Angeles School of Law 
Martha Marrapese  
Keller and Heckman LLP 
Shelah Morita  
National Nanotechnology 
Coordination Office 
Anna Muldoon  
Department of Health and 
Human Services 
James Murday  
University of Southern California 
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Food and Drug Administration 
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Environmental Protection 
Agency 
Deb Newberry  
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Paul O'Day  
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Association 
Michael Pannell  
Occupational Safety and Health 
Administration 
Carlos Pena  
Food and Drug Administration 
Elijah Petersen  
National Institute of Standards 
and Technology 
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Mark Philbrick  
Department of Energy 
Rick Pleus  
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Technology 
Rebecca Reindel  
Occupational Safety and Health 
Administration 
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Inside EPA 
Irelene Ricks  
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Colleges and Universities 
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Agency 
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RTI International 
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Agency 
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Thomas Seager  
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SA Engineering College 
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International Union, UAW 
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Jolane Souris  
Army Medical Research & 
Materiel Command 
Stacey Standridge  
National Nanotechnology 
Coordination Office 
Jeffery Steevens  
Army Corps of Engineers 
David Steup  
Shell International 
Lisa Strutz  
Army Center for Health 
Promotion and Preventive 
Medicine 
Lawrence Tamarkin  
CytImmune Sciences, Inc. 
Clayton Teague  
Independent Consultant 
Treye Thomas  
Consumer Product Safety 
Commission 
Carla Treadwell  
Navy Bureau of Medicine and 
Surgery 
Kim Tuminaro  
Department of State 
Patricia Underwood  
Office of the Secretary of 
Defense, AT&L, I&E 
Megan Velez  
Food and Drug Administration 
Greg Weatherman  
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James Weeks  
Department of Labor 
Mine Safety and Health 
Administration 
Gavin West  
Center for Protection of 
Workers' Rights 
Jay West  
American Chemistry Council 
Gladys White  
Georgetown University 
Ronald White  
Center for Effective Government 
Lloyd Whitman  
National Institute of Standards 
and Technology 
Mark Wiesner  
Duke University Center for the 
Environmental Implications of 
NanoTechnology 
Michael Winchester  
National Institute of Standards 
and Technology 
Gabriele Windgasse  
California Department of Public 
Health 
Amanda Ziegler  
James River Insurance
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Appendix C. List of Acronyms 
ACGIH American Conference of Governmental Industrial Hygienists 
ANSI American National Standards Institute 
ASTM American Society for Testing and Materials 
ATSDR Agency for Toxic Substances and Disease Registry 
CBI confidential business information 
CHA Chemical Hazard Assessment 
CNS Center for Nanotechnology in Society 
CNT carbon nanotube 
CoT Committee on Technology [NSTC] 
CPSC Consumer Product Safety Commission 
CPWR Center for Construction Research and Training 
DOD Department of Defense 
DTSC Department of Toxic Substances Control [California] 
EHS environment(al), health, and safety 
ELISA enzyme-linked immunosorbent assay 
ENM engineered nanomaterial 
EPA Environmental Protection Agency 
EU European Union 
EC European Commission 
FDA Food and Drug Administration 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
GRAS Generally Recognized As Safe 
ILSI International Life Sciences Institute 
IP intellectual property 
ISO International Organization for Standardization 
MSDS material safety data sheet 
nanoEHS nanotechnology-related environmental, health, and safety 
NAS National Academy of Sciences 
NCI National Cancer Institute [NIH] 
NCL Nanotechnology Characterization Laboratory [NIH/NCI] 
NEHI Nanotechnology Environmental and Health Implications Working Group [NSET] 
NGO nongovernmental organization 
NIOSH National Institute of Occupational Safety and Health 
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NIST National Institute of Standards and Technology 
NMSP Nanoscale Materials Stewardship Program [EPA] 
NNCO National Nanotechnology Coordination Office 
NNI National Nanotechnology Initiative 
NRC National Research Council of the National Academies 
NRDC Natural Resources Defense Council 
NSET Nanoscale Science, Engineering, and Technology Subcommittee [NSTC] 
NSF National Science Foundation 
NSTC National Science and Technology Council 
NYU New York University 
OARS Occupational Alliance for Risk Science 
OECD Organisation for Economic Co-operation and Development 
OEL Occupational Exposure Limit 
OSHA Occupational Safety and Health Administration 
PBT persistent, bioaccumulative, and toxic 
PNAS Proceedings of the National Academy of Sciences 
PPP public–private partnership 
QbD quality by design 
QSAR quantitative structure–activity relationship 
R3 risk assessment, risk management, and risk communication 
R&D research and development 
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals Act [EU] 
SBIR/STTR Small Business Innovation Research/Small Business Technology Transfer 
SCOEL Scientific Committee on Occupational Exposure Limits [EC] 
SDM structured decision making 
SDS safety data sheet [formerly MSDS] 
SNUR Significant New Use Rule [EPA] 
TLV threshold limit value 
TONIC Translation of Nanotechnology in Cancer [NCI] 
TSCA Toxic Substances Control Act 
UAW United Automobile Workers 
UCLA University of California, Los Angeles 
UCSB University of California, Santa Barbara 
UVA Ultraviolet A 
UVB Ultraviolet B 
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Appendix D. Available Tools and 
Information Repositories 
U.S. Government12 
DOD 
• US Army NanoExPERT Tool Box [140]. 
DOE 
• “Control Banding Nanotool” (Figure 6.1 on p. 27), which incorporates Lawrence Livermore 
probability and risk severity scores for risk assessment in the face of incomplete information and 
uncertainty [55]. 
EPA 
• 2012 RTI study funded by EPA on methods for prioritizing research areas on hypothetical use of 
multiwalled CNTs in upholstery fabric based on stakeholder input [113]. 
FDA 
• Pre-submission consultation with the FDA [141]. 
• Guidance documents [104]. Specifically mentioned: 
o Pharmaceutical Development [130]. 
o Quality Risk Management [134]. 
o Pharmaceutical Quality System [135]. 
o Principles of Quality by Design [130]. 
NIH 
• Nanotechnology Characterization Laboratory [136] materials testing and fundamental 
information on ENMs related to cancer (NIH/NCI). 
• The NCI Translation of Nanotechnology in Cancer group has assisted in the development of 
nanomedicines for cancer treatment by encouraging collaborative industry and government 
agency efforts [137]. 
• National Center for Biotechnology Information PubMed database of research studies [103]. 
NIOSH 
• Nanotechnology Field Studies Effort [99]. 
• Guidance documents: 
o Workplace Safety & Health Topics: Nanotechnology [114]. 
o General Safe Practices for Working with Engineered Nanomaterials in Research Laboratories 
[119]. 
NIST 
• NIST standard reference materials [116]. 
                                                          
12 The references in this list may be found in Chapter 10 (References). 
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NNCO 
• Industry and State Liaison point of contact (Dr. Michael Kiley, mkiley@nnco.nano.gov, 
703.292.4399). 
• Contact information for Federal decision makers (www.nano.gov/partners). 
• List of regional, State, and local resources (www.nano.gov/initiatives/commercial/state-local). 
• Resources for business development and technology transfer (www.nano.gov/ 
businessdevelopment). 
• A FAQ page for nanotechnology business development (www.nano.gov/bizfaqs). 
• Information on opportunities for collaboration and funding (www.nano.gov/ 
collaborationsandfunding), including a list of open contests and challenges 
(www.nano.gov/ContestsAndChallenges). 
• A database of publications and resources including budgets, strategic documents, workshop 
reports (www.nano.gov/publications-resources). 
• List of NNI Environmental, Health, & Safety-Related Documents (www.nano.gov/ 
EHSdocuments). 
• Information on Federal Legislation and Congressional Events (www.nano.gov/you/government-
legislation). 
OSHA 
• A database is in development for identifying the potential hazards posed by nanomaterials (see 
p. 36). 
• Safety data sheets (SDSs, formerly known as MSDSs). 
International 
• TEMAS—The Swiss Precautionary Matrix for Synthetic Nanomaterials is a tool “made to support 
all interest groups having a responsibility for the safety of workers, consumers or the 
environment” [109]. 
• Publications from Germany’s Permanent Senate Commission for the Investigation of Health 
Hazards of Chemical Compounds in the Work Area [127]. 
• NanoRiskCat, a risk categorization framework developed in Denmark, is “able to identify, 
categorize and rank exposures and effects of nanomaterials used in consumer products based 
on data available in the peer-reviewed scientific literature and other regulatory relevant sources 
of information and data” [110]. 
• The European Registration, Evaluation, Authorisation, and Restriction of Chemicals program 
approach to nanomaterials, initiated through European legislation [89]. 
• Publications from the Scientific Committee on Occupational Exposure Limits of the European 
Commission [129]. 
• Documentation from the International Organization for Standardization [58] and its online 
browsing platform [62]. 
• Publications from the Organisation for Economic Co-operation and Development addressing the 
safety of ENMs [115]. 
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State and Local 
• Contact information for State, regional, and local resources on nano.gov (see NNCO on p. 73). 
• California’s Safer Consumer Products Regulation “alternatives assessment” [81]. 
• Guidance from the Massachusetts Office of Technical Assistance and Technology on the safe 
development of nanotechnology [118]. 
Private 
• List of industry collaborators on nano.gov (see NNCO on p. 73). 
• Documentation from the American Society for Testing and Materials [57]. 
• Dr. Tom Seager’s life cycle assessment framework that assesses the EHS implications of a 
technology when data are sparse (see Figure 6.4 on p. 32). 
• Germany’s Federal Institute for Materials Research and Testing Nanoscale Reference Materials 
[64] website. 
• GreenFacts [139] as an example of a resource that communicates EHS information to a lay 
audience. 
• GreenScreen [87] can be used to screen and communicate hazard information on specific classes 
of nanomaterials. 
• Nano GO Consortium standardized methods for assessing the health and safety of engineered 
nanomaterials [97]. 
• Nanomaterial Registry [63]. 
• Nanotechnology Standards Database, sponsored by the American National Standards Institute 
(ANSI) Nanotechnology Standards Panel [61]. 
• National Academy of Engineering (NAE) and National Academy of Sciences reports. 
• Occupational Exposure Limits from the American Conference of Governmental Industrial 
Hygienists TLV Committee [126]. 
• Safe-and-Green-Nano List, an open-source online information clearinghouse for information on 
the safe development of nanomanufacturing and the potential for greener products through 
nanoscience [142]. 
• Structured Decision Making tool under development at CNS-UCSB: A nanotechnology risk 
screening tool [33] for structured decision making to account for motivated cognition. 
• The “Good Nano Guide,” serving as an “Internet-based collaboration platform specially designed 
to enhance the ability of experts to exchange ideas on how best to handle nanomaterials in an 
occupational setting” [98]. 
• The Insurance Services Office [122]. 
• The Occupational Alliance for Risk Science of Toxicology Excellence for Risk Assessment [128]. 
• The proprietary nanotechnology risk assessment tool called the Zurich Nanotechnology 
Exposure Protocol [121]. 
• The publications database [102] available at nanoHUB.
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